Identification and characterisation of differentially displayed transcripts in metastatic versus non-metastatic cells of the CSML cell line system by Hulgaard, Egil Fabritius
Open Research Online
The Open University’s repository of research publications
and other research outputs
Identification and characterisation of differentially
displayed transcripts in metastatic versus
non-metastatic cells of the CSML cell line system
Thesis
How to cite:
Hulgaard, Egil Fabritius (1998). Identification and characterisation of differentially displayed transcripts in metastatic
versus non-metastatic cells of the CSML cell line system. PhD thesis. The Open University.
For guidance on citations see FAQs.
c© 1998 Egil Fabritius Hulgaard
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Identification and characterisation of differentially 
displayed transcripts in metastatic versus non­
metastatic cells of the CSML cell line system.
A thesis submitted fulfilling the requirements of the 
Open University for the degree of 
Doctor of Philosophy
By: EgilX^Hulgaard
m
Sponsoring establishment: The Danish Cancer Society
Strandboulevarden 49 
DK-2100 Copenhagen 
Efh@cancer.dk
Under Ihe supervision o f
Dr. Brian Clark (ectemal supervise) and
Dr. Eugene Lnkanidin (internal supervisor).
Copenhagen, November 1998
ProQuest Number: 27696798
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27696798
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract:
Metastasis is a complex multistep process allowing otherwise localised tumour cells 
to migrate to other organs. To elucidate this mechanism further we compared the 
mRNA level of non-metastatic CSML-0 to metastatic CSML-100 and VMR-Li using 
differential display. This approach led to the identification of ten different genes 
differentially expressed between two closely related CSML cell lines. Cloning, 
sequencing and database analysis suggested the cloned fragments to be related to six 
genes with known coding sequence. MMTV, Collagen XI a  1 and PACE4 were found 
in CSML-0, while Cystatin C, Lamin C and Ly-6A/E were upregulated in CSML-100. 
Also four fragments, NN18 found in CSML-0 and NN9, NN30 and NN32 found in 
CSML-100, not related to any known gene were cloned. When tested against a panel 
of mouse tumour cell lines, a pattern of expression for Collagen XI a l ,  PACE4,
Cy statin C, Lamin C, Ly-6A/E, NN9 and NN30 connecting these genes to the 
metastatic process were found. Cystatin C protein staining of cell lines and CSML 
tumour tissue further suggested an involvement of this proteinase inhibitor in tumour 
progression. This is the first report connecting PACE4 and Collagen XI a  1 to tumour 
progression and points to new proteins potentially.utilised by colonising cells. The 
NN30 gene fragment was selected for further identifieation and eharacterisation. The 
full-length clone revealed a 338 amino acid 39 kDa protein, lacking obvious . 
homologues in the EMBL database. We temporarily named this protein E30. In situ 
hybridisation and immunostainings demonstrated that this protein was highly 
expressed in epithelial cells, in testis and in ovary, in embryonic tissue as well as in 
extra embryonic. This gene is part of a previously undescribed gene family as 
indicated by human and C. elegans ESTs homologous to E30. Transfection of E30 
into non-metastatic CSML-0 cells rendered these cells metastatic in 2 out of 3 mice in 
an experimental metastasis assay. Metastatic nodules were not only confined to the 
lung, but both mice produced liver metastasis. I therefore report the cloning of a gene 
expressed in epithelial cells and capable of inducing metastasis to the liver and lung.
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1. Introduction
Mechanism of metastasis is poorly understood
Metastasis is a multistage process, requiring a number of abilities of the colonising 
cell, abilities not possessed by any one normal cell. The metastatic cell must 1) 
dissociate from the primary tumour, 2) make its way through the extracellular matrix 
(ECM), 3) intravasate to either the blood stream or lymphatic system, 4) survive 
unattached, while avoiding the immune defence, 5) stop at or adhere to a proper site, 
extravasate into foreign tissue and 6) proliferate, generate blood supply etc. therein 
(1). Though, the events leading to the appearance of the cancer cell are being 
increasingly understood the behaviour of the metastatic cell is comprehended to a 
much lesser extent. The reasons for this are many. Firstly, when looking at tumour 
cells and their ability to proliferate the interplay between the tumour cell and the 
surrounding tissue is less complex, simplifying the system being investigated. Also, 
several pathways used by the detached cells are available making conclusions 
dependent on the system investigated. It is likely that the pathways used by the 
metastasising cell depend on the origin of the tumour, i.e. the location in the organism 
and the origin of the cell. However, even when this is taken into account general 
conclusions have been difficult to make.
Several natural processes mimic the mobile and invasive behaviour acquired by the 
metastatic cell. These include acquisition of abilities necessary for kératinocytes 
during wound healing, mesenchymal cells during embryogenesis, trophoblast to form 
the placenta and lymphocyte migration. The transitions following induction of the 
abihties of these cells lead to changes for example from an epithelial-like to a more 
anaplastic mesenchymal like morphology. Some sort of master switch or switches 
inducing these transformations in normal cells could be activated during mahgnant 
transformation, thus enabling the mahgnant cell to move to and invade foreign tissue. 
However, this remains to be proven.
It is difficult if  not impossible to separate the functional processes necessary for 
tumourigenesis and metastasis. Anyway, in order to describe the requirements for the 
metastatic process, proteins crucial for this process have been identified. The
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identified proteins have roughly been divided into five groups; 1) Proteins working in 
adhesion primarily thought to sequester the tumour cells in the tumour, but e.g. in the 
case of integrins also beheved to be essential for the homing of the mahgnant cell. 2) 
Proteolytic enzymes shown to be in action during intravasation and perh^s during 
extravasation breaking down the basal membrane enabling cells to escape into and out 
o f the blood stream. 3) Proteins involved in the mobihty of cells, since it is generally 
beheved that in order to spread fi-om one site to another, the cell must have the abihty 
to move by its own force. 4) Once in the bloodstream cells are prone to anoikis, the 
process of sq)optosis hable for unattached cehs. It is therefore likely that not only the 
cells inside the primary tumour, but also the metastatic cell must be protected against 
^optosis. 5) Prohferation at the secondary site probably requires either the abihty to 
utilise growth factors residing at this site or independence from otherwise vital factors 
in the environment.
This is not a comprehensive overview of all the knowledge concerning metastasis, 
since the amount of hterature on the subject is much too overwhelming. Rather it is a 
subjective choice of biological proteins or protein systems thought to play a role in 
metastasis. The object of the thesis was to identify differences between two cell lines 
with different metastatic potential. This angle of approach leads to focus on single 
proteins functionally involved in this process.
Adhesion
Almost 90% of all tumours are of epithehal origin, a group of cells containing 
adhesion molecules binding with strong homotypic affinity. During the outgrowth of 
the primary tumour these adhesion proteins are thought to keep the cells together. 
However, cell adhesion serves opposite functions during tumour progression. On one 
site adhesion is thought to maintain non-metastasising cells inside the primary tumour 
thereby avoiding metastasis, on the other some adhesion molecules are possibly 
required for motility, homing and growth stimulation. Though many more adhesion 
molecules have been described only E-cadherin, the integrins and CD44 will be 
described here. The best-investigated example of a cellular adhesion molecule 
negatively controlling the progress of the tumour is E-cadherin.
E^adherin
E-cadherin is part of the cadherin family of calcium dependent adhesion molecules 
consisting of more than 30 members. The 135kDa precursor is processed to yield the 
120kDa mature protein. Extracellularly five CAD repeats are encountered containing 
two conserved regions, which are the putative calcium-binding sites (2; 3). The 
outermost domain contains an HAV-sequence essential for homophihc recognition 
also found in other cadherins, although flanked by other amino acids. The 31 amino 
acids comprising the transmembrane region connect the extracellular part to the 
highly conserved cytoplasmic domain (4). A 30 amino acid region comprises the 
recognition site for catenins intracellularly (4; 5). The tail complexes two sets of 
catenin: one complex consists of a-catenin, y-catenin and E-cadherin, while the other 
is composed of a-catenin, B-catcnin and E-cadherin (6; 7). Another catcnin-like 
protein, pl20-cas, has been found to be part of these complexes (8). Catenins are 
beheved to form the link between the actin cytoskeleton and E-cadherin. First, it 
seems, B-catenin binds E-cadherin, while it is being transported to the plasma 
membrane, thereafter a-catenin connects this complex to actin (7; 9; 10). This 
complex is in the normal cell part of the adherens junctions and expressed at the 
basolateral surface of epithehal cells (11).
Two types of studies have imphcated E-cadherin in metastasis. Firstly, expression 
studies of invasive tumours indicate a downregulation. Secondly, experimental up- 
and downregulation of E-cadherin lead to inhibition and induction of invasion, 
respectively. Downregulation of E-cadherin has been found in a number of 
carcinomas. As a general rule E-cadherin downregulation was correlated with 
mahgnancy parameters, such as tumour progression, loss of differentiation, invasion, 
metastatic potential and poor prognosis (12). Also, transfection experiments inducing 
expression of E-cadherin into otherwise non-expressing cell lines inhibited invasion 
and metastasis (13; 14), while antisense expression downregulating E-cadherin 
expression induced invasion (14). Induction of invasion could also be achieved by the 
use of monoclonal antibodies against E-cadherin (13; 15). Though the expression of 
E-cadherin therefore closely correlates with metastasis, metastatic E-cadherin cell 
lines have been reported, indicating its functional inactivation. This could be caused 
by mutations impeding adhesion or function of the cytoplasmic tail, or could be
caused by downstream regulators, like the catenins. In vitro it was shown that 
mutations in domains involved in complex formation with the catenins (9) in calcium 
binding (2) or in enzymatic processing of the precursor protein (16) impaired 
aggregation and/or compaction.
Though point mutations are infrequent, mutations in exon 7, 8 ,10,12 and 13 
representing the extracellular part of E-cadherin and in exon 16, a part of the 
cytoplasmic tail have been described for some carcinomas (12). As mentioned this 
could lead to a non-functional E-cadherin. Also downregulation of one of the 
catenins could lead to E-cadherin inactivity as described for a-catenin (17) and B- 
catenin (10; 18; 19).
E-cadherin functions via catenins, a complex of E-cadherin, a-catenin and B-catenin 
or y-catenin (plakoglobin) binds the actin cytoskeleton. B-catenin was found to be a 
close homologue of armadillo a drosophila gene part of the wingless pathway (20) 
and seems to be a component of the homologous mammalian wnt pathway active 
during tumour progression (21). B-catenin was also shown to associate with the 
protein adenomatous polyposis coh (APC), thereby regulating the intracellular B- 
catenin level (22; 23). APC has been found to be truncated in the hereditary colon 
cancer familial adenomatous polyposis (FAP) and B-catenin does not bind truncated 
APC (22). A regulatory function of B-catenin was indicated when it was found that it 
binds the transcription factor tcfrlef-1, leading to translocation of B-catenin to the 
nucleus (24-26).
All in all there is compelling evidence for the involvement of functional E-cadherin in 
prevention of cancer metastasis. However, the mere homophihc adhesion of E- 
cadherin is not sufficient, as intracellular proteins mediate binding to the actin 
filaments and participate in signalling. At least P-catenin seems to be an important 
moderator of E-cadherin adhesion.
Integrins
While E-cadherin is believed to impede spread of cancer cells, other adhesion 
proteins, like the integrins have more complex functions. These adhesion proteins are 
a growing family of heterodimeric integral plasma membrane proteins mediating 
adhesion to the ECM or other cell surface proteins most of which belong to the 
immunoglobulin superfamily (27-29). Each heterodimer is composed of one a  and 
one B subunit. Though, more than 16 a  and 7 B units have been discovered, 
theoretically allowing more than 100 combinations, only a little more than 20 of these
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Figure 1.1: The integrin receptor family. A schematic representation of various ap integrin 
heterodimers and the ligands they interact with. COLL: collagenj FN: flhronectin, LM: 
laminin, ET: entactin, Kal: kalikyein, Mer: merosin, BL: hasal lamina, VCAM: vascular cell 
adhesion molecule, ICAM: intercellular cell adhesion molecule, F6: fihrinogen, VN: 
vitronectin, TS: thrombospondin, OP: osteopontin, VWF: Von Willehrand factor, RGD: 
ArgdyAsp-peptide, MadCAM mucosal address in cell adhesion molecule. From (31):
combinations, have been described (Fig. 1.1). The a  and B subunits contain an
extracellular domain much larger than the carboxy-terminal intracytoplasmic domain
except for B 4, due to the very large cytoplasmic domain of this subunit (30). Each of
the identified integrins has a unique recognition pattern, binding either ECM
components like fibronectin, collagen or laminin, or mediating adherence to other
cells via e.g. VCAM-1 or ICAM (31).
The sequence recognised most frequently consists of the integrin-binding site RGD, 
but depends on the specific combination of a  and B subunits. For example all a-v
containing integrins have been shown to bind this site, while no fi-2 containing 
integrin does (32).
While integrins in general are ubiquitously expressed^ there are variations in the 
expression of the specific integrin. The most promiscuous partner, integrin B-1, that 
mediates binding to the ECM, is ubiquitously expressed, while the integrin a-4 B-1 is 
unique among the B-1 integrins in that it is restricted in its expression to bone 
marrow-derived cells, except for neutrophils (33) on certain tumour cells and in 
muscle development (34). The leukocyte-specific integrin a-E  B-7 binds E-cadherin 
and this may represent a mechanism by which these lymphocytes remain in then- 
respective epithelial tissue (35).
Binding not only mediate adhesion. Rather integrin-binding set off a number of 
intercellular events leading to survival, motility and proliferation of normal and 
tumour cells. Central to the many roles that integrins play is integrin-mediated signal 
transduction processes. Evidence is surfacing that integrins can activate the MAP- 
kinase pathway, through which several nuclear transcription factors are activated. 
When fibroblasts attach to fibronectin, MAP kinase is activated (36; 37). This 
activation could occur via Ras, since activation of integrin a-2 B-1 results in 
accumulation of GTP-bound Ras (38), and via tyrosine phosphorylated focal adhesion 
kinase (FAK) (37). Also the stimulation of tyrosine phosphorylation, by insulin, of the 
insulin receptor substrate, IRS-1, results in the association of phosphorylated IRS-1 to 
a-v B-3. It was demonstrated that insulin stimulated proliferation led to enhanced 
proliferation when cells were plated on vitronectin, a ligand for integrin a-v B-3 (39).
Normal epithelial, endothelial cells as well as some tumour cells die when deprived of 
the ECM. However, constitutive activation of intracellular signal proteins (that are 
often oncogenes) allows the cells to survive, despite the lack of integrin attachment. 
Also, overexpression of integrin a-v B-3 on human melanoma cells increased their 
survival in Matrigel (40). Their increased survival could be due to induced expression 
of the ^optosis suppressor Bcl-2 (41).
A significant role for integrin a-v  B-3 in the process of angiogenesis has been 
reported. During angiogenesis this integrin was upregulated (42), while antibodies to 
this protein inhibit angiogenesis, but had no effect on pre-existing vessels.
There is overwhelming evidence that integrins contribute to tumour progression. 
Integrin a-v  B-3 are required for metastasis of melanoma cells (43-46). Expression of 
this promiscuous integrin allows the cell to respond to almost any matrix protein it 
may encounter. Also, integrin a-v  B-3 has been shown to bind MMP-2 in an active 
form thereby localising this protease on the surface of invasive tumour cells (47). The 
integrin a-2 B-1 have been associated with metastasis of human rhabdomyosarcoma 
cells inducing both experimental and spontaneous metastasis (48). Association of 
MMP-1 expression to integrin a-1 B-2 expression has also been suggested (49). The 
involvement of B-1 integrin during metastasis was confirmed, since the disruption of 
integrin a-4  B-1 and integrin a-6 B-1 fimction reduces the metastatic capability of 
highly metastatic ESb murine T-lymphoma cells (50). Curiously, this changed the 
organ preference of the metastasising cells fi-om spleen and liver in highly metastatic 
non-mutated ESb cells to skeletal muscle in reduced metastatic ESb knock out 
mutants.
CD44
CD44 is another transmembrane adhesion protein implicated in metastasis (51). The 
extracellular part has been shown to bind a variety of proteins but is generally 
accepted as a hyaluronic acid (HA) acceptor (52). HA is a polysaccharide consisting 
of a linear polymer of repeating disaccharide units of high molecular weight (10^- 
lO^kDa) and an integral part of the ECM. CD44 is a glycoprotein built of 10 exons in 
its standard form (CD44s), where the primary 7 exons are extracellular and exon 8 
contains the transmembrane region. One of the last two exons code for the 
cytoplasmic tail: exon 9 represents the short tail form of CD44 containing a 
cytoplasmic tail of only 3 amino acids, while transcripts containing exon 10 results in 
a protein with a cytoplasmic tail of 70 amino acid. These 70 amino acids have been 
shown to contain a number of phosphorylation sites of which at least two are 
constitutively phosphorylated. The tail of CD44 has been shown to interact with the 
microfilament through ezrin-radixin-moesin (53). A number of splice variants has
been described in which 10 different inserts (CD44V1-10) inserted after exon 5 have 
been identified e.g. the epithelial form containing V8-10 and the keratinocytic form 
containing V3-10.
CD44 was initially discovered as a brain-granulocyte-T lymphocyte antigen and 
connected to metastasis, when CD44 high expressing cells sorted fi-om low- 
expressing cells revealed a higher metastatic capability (54). The most convincing 
evidence comes firom transfection of non-metastatic rat pancreatic tumour cells with 
the CD44 variant form pMeta-1 (CD44V4-7) or pMeta-2 (CD44V6-7) (55; 56). This 
induces the ability to form lung nodules 40-60 days after injection sc of 5x10^ cells.
Proteolysis
An early observation of tumour tissue connected to tumour progression was the 
degradation of the basement membrane. This has been shown to involve one or more 
proteases controlled by their corresponding inhibitors. Several proteolytic systems 
thought to be involved in invasion and metastasis have been described, involving 
proteases of all five major classes (i.e. the serine, aspartic, cysteine, threonine, and 
metalloproteinases). The major enzymes in each of these classes of proteases seem to 
be the serine protease urokinase plasminogen activator (uPA), the matrix 
metalloproteinases MMP-2 and MMP-9 and the cysteine proteinase Cathepsin B.
Plasminogen activation system
During the past decade increasing evidence has evolved, implicating uPA in cancer 
metastasis. There appears to be general agreement on the notion that the related tissue 
type plasminogen activator (tPA) is primarily involved in thrombolysis. The reaction 
pathway of uPA involves its uPA receptor (uPAR), the plasminogen activator 
inhibitors (PAI-1 and PAI-2), controlling the activation of plasminogen to plasmin. 
The major target of plasmin is fibrin, but several studies have shown a broad spectrum 
of degradation of the ECM components like fibronectin and vitronectin (57). Also 
plasmin has been shown to activate otlier matrix degrading enzymes e.g. 
metalloproteinases. Activation of uPA has been shown to be enhanced when bound to 
uPAR. This activated pair can be inhibited by PAI-1, that when bound promotes 
endocytosis of this complex. Staining of tumour tissue for members of this system
shows PAI-1 expressed inside the tumour, while uPA and uPAR very often are 
situated at the invasive fix)nt (58; 59). The uPAR or uPA can be expressed by the 
cancer cells or the surrounding stroma cells, thereby assisting in breakdown of the 
ECM and tumour invasion.
Transfection experiments introducing uPAR into rat breast cancer cells (60) or 
antisense inhibiting uPAR expression in human epidermoid carcinoma cell line (61), 
respectively elevated and reduced metastatic capacity of the transfected cells. 
Elevating the expression of uPAR increases the number of metastatic nodules with a 
factor 3 to 5 and allows for metastasis formation in liver and spleen, organs otherwise 
not invaded. uPA expression also influences the metastatic capacity of murine B16 
melanoma cells (62) and rat prostate cancer cells (63). Increased metastatic formation 
in the lung and skeletal muscle correlated with elevated levels of uPA in these cells. 
Furthermore, downregulation of uPA in metastatic B16-F10 cells reduced number of 
lung colonies formed. These notions support the involvement of uPA and uPAR in 
metastasis. However, other proteolytic systems connected to the uPA system play 
important part in tumour progression as well. One of these systems are the gelatinases 
MMP-2 and MMP-9.
Matrix metalloproteinases (MMPs)
The MMPs are a family of zinc dependent, secreted or transmembrane proteases able 
to degrade components of the ECM and the basement membrane (Fig. 1.2) originally 
identified as enzymes responsible for the dissolution of the tadpole tale. The proteases 
are exported as zymogens awaiting further extracellular activation. They are divided 
into three major subgroups by their substrate specificities: collagenases (MMPx-y) 
degrade fibrillar collagen, stromelysins (MMPz-u) prefer proteoglycans and 
glycoproteins, while the gelatinases (MMP-2 and MMP-9) degrade nonfibrillar and 
denatured collagen (gelatine) (64). Once activated the MMPs are susceptible to 
inactivation by a number of inhibitors, most notably one of the four known tissue 
inhibitors of metalloproteinases (TIMPs)
The MMPs has been associated to the metastatic process for more than 15 years (65; 
66) and further sustained to date (67). These investigations demonstrates that the 
number of MMP family members found tends to increase with progression and that
the MMPs detected could be expressed by the tumour cells, but also by the
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Figure 12: The family of matrix metalloproteinases. Subgroups are arrangeii by domain structure and 
separated by a dashed line. Within the largest, hemopexin-domain subgroup, family members with 
some distinct but subtle structural features are separated by a dotted line. MT: membrane type, PRE: 
leader sequence, PRO: prodomaln, H: binge domain, hrm; hemopexin-iike domain, F: furin consensus 
site, FN: fibronectin like domain, TH: transmembrane domain, NJ).: not determined. From (64).
surrounding stromal cells.
From early on the focus was on proteinases degrading type IV collagen, a major 
structural protein in the basement membrane, that is the MMP-2/gelatinase A/72 kDa 
type rv  collagenase and MMP-9/gelatinase B/92 kDa type IV collagenase. The 
primary purpose of these proteases in tumour malignancy (along with other 
proteolytic enzymes) is thought to be the breakdown of the physical barrier between 
the primary tumour and sites of metastasis, i.e. dissolution of the basement membrane 
during intravasation and extravasation. MMP activity has been shown to be linked to 
the invasive potential of tumours through detection in metastatic cell lines (68; 69).
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Moreover the elevated collagenolytic activity correlates with stage in colon and 
bladder cancer (70; 71).
Activation of proMMP-2 through MTl-MMP surface binding and integrin a-v B-3 
(47; 72) localises this system to the membrane indicating an involvement in 
metastasis formation. Indeed, overexpression of MMP-2 and MMP-9 in non- or low- 
metastatic cell lines induces the metastatic phenotype (73-76). Inhibition of tumour 
invasion could be obtained using Marimastat (BB-2516) a protease inhibitor blocking 
proteolysis (77). However, natural inhibitors regulate the activity of the MMPs and 
changing the quantity of inhibitors also affect metastasis formation.
Manipulation of the TIMP-1 and TIMP-2 expression level using antisense or sense 
transfections indicates a role for these inhibitors in tumour progression. Reducing the 
level of TIMP-1 in Swiss 3T3-cells induced the formation of metastatic tumours in 
nude mice (78), while overexpression reduced metastatic ability of human gastric 
KKLS cancer cells to the chick embryo (79) and of B16F 10-cells (80). Also Schultz 
et al. (81) demonstrated the ip injection of recombinant TIMP-1 reduced formation of 
lung nodules by B16F10 melanoma cells. However, there are examples of systems in 
which TIMPs have no effect or enhance tumour ^ w ü i  and/or metastasis (82) and 
conversely, that TIMP-1 and TIMP-2 also show growth promoting effect (64; 83).
Cathepsin B
Also the cysteine protease Cathepsin B has been implicated in cancer metastasis (84). 
This ubiquitously expressed proteinase was identified as a lysosomal enzyme secreted 
under physiological and malignant conditions (85; 86). The protein is often secreted 
as an inactive protein and inhibited by members of the cysteine protease inhibitor 
family, most notably Stefin A (Cystatin A), Stefin B (Cystatin B) and Cystatin C. The 
ability to degrade ECM proteins (87) such as collagen and laminin and activate uPA 
(88) points to a possible role during invasion and tumour progression. Localisation of 
the protease to the plasma membrane (89-91) and to the invasive edge of tumours 
supports this notion (92). Increasing expression of Cathepsin B in murine B16 
melanoma cells correlates with metastatic ability of these cells (93; 94). Clinical 
investigations indicate activity of Cathepsin B to be part of the invasive process.
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demonstrating elevated expression of Cathepsin B in e.g. colon carcinoma (95), lung 
(96) and breast carcinoma (85). As mentioned the inhibition of Cathepsin B could be 
performed by the intracellularly expressed Stefin A or B or by the secreted Cystatin 
C. Changing the ratio of the proteolytic activity of Cathepsin B against the activity of 
the cysteine protease inhibitors shows that murine melanoma B 16 cell populations 
enriched 4-10 times in their Cathepsin B activity also displayed higher metastatic 
c^ability  (97).
Role of proteases in extravasation
By inference it has been assumed that the proteolytic activity performed by these 
enzymes was as important for extravasation and intravasation since both processes 
seems to require break down of the basement membrane. Metastatic B16F10 
melanoma cells transfected with TIMP-1 were inhibited in their ability to form 
metastatic nodules of the lung (80). This has been explained with a possible reduced 
ability to invade the lung tissue i.e. extravasate into the lung. Similar results and 
conclusions have been obtained with Cystatin C transfection of B16 cells (98). While 
additionally considering the inhibition of tumour growth along with the hampered 
metastatic ability of TIMP-transfected cells, the rate-limiting step in this context could 
shift fiom extravasation to tumour growth. However, using intravital 
videomicroscopy it was demonstrated that B16F10 melanoma cells transfected with 
TIMP-1 were shown to be growth limited but not restricted in extravasation (99; 100).
Induction of migration
As the tumour grows and progresses in many instances morphology of the cells 
change fiom epithelial to more mesenchymal. The hepatocyte growth factor (HGF) 
has been shown to induce such a change through binding to the MET receptor (101).
HGF
Several independent different groups discovering the ability of HGF to induce growth 
of hepatocytes and mobility of epithelial cells initially described HGF (also called 
scatter factor)(102; 103). HGF is secreted as an inactive single chain lOOkDa protein, 
and until now the two proteases uPA and factor XII have been identified as possible 
in vivo activators of HGF (104; 105) cleaving pro-HGF into the active ap-HGF. The
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active HGF then binds the MET receptor (106) and induces 1) release of the cell, 2) 
invasion, 3) production o f proteases enable o f ECM and basement membrane 
degradation, 4) growth and 5) polarisation in epithelial cells (107). The response to 
HGF is transient and in vitro the affected cells scattered by HGF eventually rejoin.
Several lines of evidence implicate the expression of either HGF or its receptor in 
metastasis. Transfection experiments with NIH3T3 and C l27 rendering them HGF 
and MET positive allowed for experimental metastasis to the lung (108; 109). It was 
also shown that the rare "spontaneous" lung metastasis produced in this assay by 
untransfected NIH3T3 cells overexpressed MET. In human breast cancer it was found 
that HGF is a predictor of recurrence and survival (110).
Mtsl
Motility requires reorganisation of the cytoskeleton involving actin and myosin 
binding proteins e.g. Mtsl (SI00A4). The Ca^^-binding protein was initially isolated 
from metastatic CSML-100 cells and shown not to be expressed in non-metastatic and 
low-metastatic cell lines (111). This gene product is being implicated in motility and 
invasion, since it is expressed in murine and human macrophages, T-lymphocytes, 
neutrophils and monocytes, but not in B-cells, which are non-invasive. S I00A4 
proteins of different species has been shown to associate to cytoskeletal proteins i.e. 
non-muscle myosin, non-muscle tropomyosin or actin (112-114). This possible 
involvement in motility has encouraged investigations into metastatic potential of 
M tsl. Transfection of various cell systems induce metastasis in otherwise low- 
metastatic cell lines (115-117), while antisense expression reducing the level of Mtsl 
protein impedes metastasis of otherwise low-metastatic cells (118) correlating with 
suppression of motility (119). The most compelling evidence for the involvement of 
M tsl in metastasis comes from experiments with transgenic mice (120; 121). No 
alterations in phenotype were seen in transgenic mice expressing elevated amounts of 
M tsl in the mammary gland. However, crossing these mice with GRS/A mice, who 
have high incidences of benign mammary tumours, lead to lung metastasis in 40% of 
the tumour bearing hybrids.
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Apoptosis in metastasis
Though described in 1972 (122), the importance of programmed cell death was not 
recognised until the beginning of the *90. Since then, the field has developed 
explosively e.g. involving embryogenesis, tissue remodelling, tumour development 
and recently data has evolved implicating resistance to apoptosis in tumour 
progression.
Resistance to apoptosis promotes metastasis
One of the rate limiting steps in metastasis is thought to be survival of the unattached 
cell following intravasation. It is straightforward, that survival in the blood stream 
would require the ability to resist attack fix)m the immune system and apoptosis 
resulting from the detachment from tissue (ECM, basal lamina, collagens). However, 
only few examples are described until now. DAP kinase was isolated using a 
fimctional cloning technique isolating genes involved in interferon y induced 
apoptosis (123). DAP kinase is a IfiOkDa calmodulin dependent serine/threonine 
kinase, located at the actin filamentous part of the cytoskeleton, containing a C- 
terminal death domain (124). Its expression is often lost in human B-cell lymphoma 
cell lines (125). When comparing murine Lewis (3LL) and CMT64 lung carcinoma 
cell lines for DAP kinase expression low metastatic cell lines expressed higher 
amounts than their highly metastatic counterparts. Transfection experiments revealed 
a reverse correlation between level of expression and metastatic capability in 3LL 
cells, while sensitivity to TNF a  induced apoptosis increased (126). Analogous results 
have been reported by Shtivelman (127), who, using differential display (DD), 
isolated CC3 firom low metastatic human c-SCLC cell hnes. Highly metastatic v- 
SCLC cell lines did not express this gene. The ability to metastasise to grafts of 
human foetal lung in SCID-hu-L mice was almost completely abolished for CC3 
transfected v-SCLC cells. This was explained by a higher susceptibility to apoptosis 
since TUNEL staining of tumours and cultivation transfected cells in 0.5% serum 
increased apoptosis. Using transgenic mice expressing B c1-xl under the control of the 
keratin 14 promoter it was shown that the affected mice are more susceptible to 
chemical induction of tumours and that these tumours frequently undergo malignant 
conversion (128). These reports are in agreement with the generally believed 
conception of metastasis, where the stress imposed on the evading cell after
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detachment from the ECM and in circulation must require greater resistance to 
apoptosis. The contrary was demonstrated^ when transfecting EGFR into low 
metastatic rat mammary adenocarcinoma MTC cells (129). This made the transfected 
cells more susceptible to apoptosis, while increasing their metastatic potential. 
Apoptosis was linked to cell cycle stage, since TGF a  treatment halved the amount of 
cells in G2/M. Hence, expression of proteins protecting metastatic cells from 
apoptosis, while in the process of spreading (B c1-xl  and EGFR) are upregulated 
during metastasis. Expression of proteins typical of low-metastatic cells impeding 
metastasis (DAP kinase and CC3) on the other hand is reduced.
Induction of apoptosis promotes metastasis
While the metastatic cells are thought to resist apoptosis, metastatic colonic 
adenocarcinomas have been suggested to induce ^optosis by production of the Fas 
ligand. The Fas ligand is expressed in immunologically privileged sites in the body 
and thought to play a role in deletion of activated T lymphocytes at these sites (130). 
The ligand was also present on the metastatic cells invading the liver and suggested to 
induce apoptosis in T lymphocytes and in Fas expressing hepatocytes.
Growth induction in target organs
Survival of the detached cells enables it to circulate to a distant site and adhere 
specifically to the endothelial cells of the organ or get tr^p ed  in the c^illaries of e.g. 
the lung. This arrest could lead to invasion into the organ and proliferation. However, 
many tumour cells are not enab le  of proliferation in the foreign tissue. There is an 
incompatibility between the seed and the soil.
The explanation for this could be several, one being that the foreign tissue lacks 
growth factors crucial to the invading cells. Cultivation of prostate carcinoma cells 
with conditioned media fix>m fibroblasts of different tissue pointed to bone fibroblasts 
as growth stimulatory. Stimulation of the cells was mutual since conditioned media 
from the carcinoma cells stimulated the bone fibroblasts. This is of interest since bone 
is a common metastatic site of prostate cancer (131). In the same line of evidence 
highly metastatic 3LL lÆwis Lung carcinomas express high amounts of the PDGFa- 
receptor, while low metastatic clones downregulated this receptor. Up or
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downregulation of this receptor in low or high metastatic clones, respectively, 
enhanced or reduced the metastatic c^ability in the affected cells (132). Several 
other lines of evidence point to specific factors in the organ as determinants for 
metastasis formation (133; 134). As the primary cells seek to metastasise there seem 
to be one or several organs of preference. One of the explanations for this preference 
is probably the ability to grow in an environment of specific growth factors. Further 
progression of the metastatic cell lines, however, probably leads to a loss of this 
preference allowing for metastasis to other organs (135).
Objective
As described in all of the above plenty of pathways can lay down the tracks for the 
cancer cell and lead it to the lung. Many different molecules facilitating adhesion, 
proteolytic degradation, growth induction etc. can render the affected cell metastatic. 
Various factors affect the metastatic abilities of each cell, factors that are likely to 
depend at least on the origin of the cell. This work is an attempt to investigate 
differences amongst three closely related adenocarcinoma cell lines, non-metastatic 
CSML-0 and metastatic CSML-100 and VMR-Li, using diflferential display. I report the 
identification of mRNA fix)m six known and four unknown genes differentially 
expressed in a panel of cells with different metastatic potential. The expression of one of 
these proteins (Cystatin C) was also demonstrated in tumour tissue fix)m CSML-100 as 
compared to CSML-0. Another of the gene fi-agments, having no homology to any 
known gene, was used for cDNA-Hbrary screening. The full length clone, temporarily 
called E30, and characterised using polyclonal antibodies and transfection experiments. 
While the antibodies suggested that E30 is a protein expressed mainly in the cytoplasm 
of epithelial tissue, the transfection experiments implicate an involvement of this gene in 
metastasis.
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2. Materials and Methods:
Cell lines: The cell lines used for DD were derived from spontaneous mouse 
mammary adenocarcinoma, and characterised as a non-metastatic CSML-0, a metastatic 
CSML-100 (136) and a metastatic VMR-Li cell lines (137), CSML-0 and CSML-100 
originated from the same tumour. The panel of cells consisted of five related 
adenocarcinoma cell line systems, the previously mentioned VMR and CSML, plus 
MTl (138), RAC (139) and Miller cells (140) and four additional cell lines, the lung 
carcinomas Linel (141) and LL-Met (142) and the fibroblast cell lines NIH3T3 and 
lOTK (143). The panel contained three non-tumourigenic cell lines (NIH3T3, IOTV2 
and RAC311C), five non-metastatic cell lines (VMR-0 p9, CSML-0, RAC 1 OP, 67NR 
and 168FARN), one cell line metastatic in a spontaneous assay only (MT1TC3), four 
cell lines displaying metastatic behaviour in the experimental assay only (VMR-0 
p25, M TITCI, RAC34E and RAC5E) and five metastatic cell lines metastatic in both 
assays (VMR-Ly, VMR-Li, CSML-100, 66CL4, 4T07, 4T1, Linel and LL-Met). The 
VMR-0 cells became experimentally metastatic when passaged from p9 to p25. The 
cell lines were grown in Dulbeccos Modified Eagles Media siqiplemented with 10% 
foetal calf serum and 4 mM Glutamax (Life Technology).
Differential display ^ D ): The DD technique is based on a selective reverse 
transcription and PCR. Firstly 1/12 of the mRNA population is selected using a polyT 
primer containing two anchoring nucleotides (in this line of experiments the A and G of 
the downstream primer TnAG). Secondly this downstream primer in conjunction with 
an arbitrary decamer upstream primer selects the cDNA fi-agments actually displayed. 
DD was performed using the RNAmsq)™ kit fix)m GenHunter (Brookline, MA, USA) 
according to the manufacturer's recommendations and as described (144). Briefly, 0.2 pg 
total RNA was reverse transcribed using superscript reverse transeriptase (Life 
Technology) and 5’-Tu AG-3* as downstream primer, followed by a PCR using the same 
downstream primer and one of 32 arbitrary 10-mers (DNA-Technology, Aarhus, DK). 
Sequences were obtained fix)m GenHunter (primers AP1-AP5), M. Strauss (primers 1- 
26) or designed for this system (primer E)(Table 2.1). Differentially expressed, 
reproducible bands were excised from the 6% denaturing polyacrylamid gel, extracted in 
boiling water, PCR amplified and purified using Qiagen kit (Qiagen, Chatworth, CA, 
USA).
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Table 2.1 : Upstream primers used for DD:
Primer Sequence Primer Sequence Primer Sequence Primer Sequence
# # # #
1 5'-TACAACGAGG-3' 9 5-TCGGTCATAG-3' 17 5'-GATCTGACAC-3' 25 5-GATCATAGCG-3'
2 5'-TGGATTGGTC-3' 10 5'-GGTACTAAGG-3' 18 5'-GATCTCAGAG-3’ 26 5’-GATCTAAGGC-3’
3 5*-CTTTCTACCC-3* 11 5’-TACGTAAGCG-3* 19 5-GATCATAGCC-3' E 5-AGGTACTGAC-3'
4 5'-TTTTGGCTCC3’ 12 5'-CTGCTTGATG-3’ 20 5'-GATCAATCGC-3' API 5'-AGCCAGCGAA-3'
5 5'-GGAACCAATC-3' 13 5-GTTTTCGCAG-3' 21 5'-GATCTAAGCG-3* AP2 5’-GACCGCTTGT-3'
6 5'-AAACTCCGTC-3' 14 5-GATCAAGTC03' 22 5‘-GATCGCATTG-3' AP3 5-AGGTGACCGT-3'
7 5-TCGATACAGG-3' 15 5-GATCCAGTAC-3' 23 5‘-GATCTGACTG-3* AP4 5-GGTACGCCAC-3'
8 5'-TGGTAAAGGG-3' 16 5"-GATCACGTAC-3' 24 5'-GATCATGGTC-3’ AP5 5-GTTGCGATCC-3'
RNA isolation and Northern blot analysis: RNA was isolated according to 
Chomczynski and Sacchi (145). In short, harvested cells were lysed in lysis buffer (4 M 
guamdiniumthiocyanat, 25 mM sodium citrate, 0.5% sodium sarcosyl, and 0.7% B- 
mercaptoethanol). After separation using an equal volume of phenol and 1/10 volume of 
chloroform, the RNA was precipitated in isopropanol and reprecipitated over night in 3.3 
M LiCl. The precipitated RNA was treated with DNAse, phenol extracted, ethanol 
precipitated and it was stored in 70% ethanol at -80®C. RNA electrophoresis was 
performed in a 1% agarose gel containing 6.5% formaldehyde and 1 x MOPS buffer (20 
mM MOPS, 5 mM sodium acetate, 1 mM EDTA) according to (146). Transfer o f RNA 
to Hybond N filters was done by capillary blotting in 20 x SSC (3 M NaCl, 0.3 M 
sodium citrate). After transfer, the filters were baked for 2 h at 80°C in a vacuum oven. 
DNA-firagments were labelled using either Meg^rime™ (Amersham, Arlington Height, 
IL, USA) as described by the manufacturer’s or PCR-labelled (18 cycles, 30 sec at 94®C, 
2 min at 40°C, 30 sec at 72°C) using 25 pCi [^^P]dCTP (Amersham, Arlington Height, 
IL, USA) and the corresponding primers. The labelled fingments were hybridised in 
hybridisation buffer (50% formamide, 5 x SSC, 10 x Denhardt's solution, 0.5% SDS and 
100 pg/ml single stranded salmon sperm DNA) at 37®C for 16-36 h. After hybridisation 
the filters were rinsed in 0.5 x SSC, 0.2% SDS once, then washed for 15 min at 37°C. 
Optional additional wadiing was done at 45®C and/or 65°C. Total RNA for the filters 
using 14 cell lines was adjusted using polyU as described (120).
Cloning and sequencing: Fragments displaying differential expression in Northern 
blot analysis were cloned into the TA pCRH-cloning vector (Invitrogen, San Diego, CA
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USA). The cloned fragments were sequenced by the use of the sequencing kit from 
Amersham (Arlington Height, IL, USA). The nucleotide sequences were compared with 
known sequences in the databases through either FASTA or BLAST (Genetics 
Computer Groiq), 575 Science Drive, Madison, Wisconsin, USA) using the services of 
the Danish Biobase.
Western blotting: Whole cell lysates were prepared by adding 10 pi 2 x sample 
buffer (100 mM TRIS (pH=6.8), 4% sodium dodecyl sulphate (SDS), 0.2% Bromphenol 
Blue, 20% Glycerol, 10% B-merc£^toethanol) to 10^  pelleted cells. Cells were boiled for 
5 min, and the proteins were separated on 15% SDS-polyacrylamid-gel (SDS-PAGE), 
and transferred to Hybond C filters by semi-dry electro blotting. Evaluation of blotting 
efficiency and amounts loaded was done by Ponceau S sluiniiig according to the 
manufacturer’s instructions. Primary antibody was ^ l i e d  in TBS-T buffer (2mM TRIS 
pH=7.6, 137mM NaCl, 0.1% Tween 20) supplemented with 10% PCS and 5% dried 
milk powder for 1 hour at room temperature. Secondary antibodies used were 
horseradish peroxidase-conjugated swine anti-rabbit or goat anti-rat immunoglobulin 
(DAKO, Glostrup, Denmark) at a 1:1000 dilution For detection, the ECL-kit 
(Amersham) was used according to the manufacturer’s instructions.
X phage-cDNA library: A cDNA library was constructed fi-om CSML-100 mRNA 
with the ZAP-cDNA synthesis kit and ligated onto Uni-ZAP XR vectors with the ZAP- 
cDNA G ig^ack m  Gold Cloning kit (Stratagene). Two plates with 150.000 
plaques/plate were blotted onto Hybond N filters (Amersham) and screened using the 
PCR-labelled DD fragment. cDNA clones were excised as pBluescript phagemids with 
ExAssist Helper Phage (Stratagene). The cDNA clones were sequenced upstream and 
downstream using the sequencing kit, v2 (USB).
In situ hybridisation: Virgin A/Sn females were allowed to mate overnight and the 
morning thereafter denoted as 0.5 dpc. Slides were prepared as described from embryos 
of stage 12.5, 14.5 and 16.5dpc and fix)m adult mouse organs (147). As specific probe 
the 1137bp E30 X phage-cDNA library firagment was excised with EcoRI and cloned 
into the pRc/CMV vector (Invitrogen). The pRc/CMV-10 vector was linearised with 
Xbal or HindlQ and RNA transcribed as described (147) using the 2q)propriate T7- or
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SP6-polymerase to produce the sense and antisense probe. In vitro transcription, 
hybridisation and washing were done as described (147) with an additional step 
involving alkaline hydrolysis for 52 min. After washing all slides were exposed for four 
weeks under NTB-2 autoradiographic emulsion (Kodak).
Fusion protein and immunisation: The full-length clone obtained from the 
CSML-100 X phage-cDNA hbrary was excised using EcoRI and ligated into pGEX- 
30X containing an in fi-ame EcoRI-site under the control of the lacZ-promoter. The 
correct orientation was confirmed using Xhol restriction site analysis. Expression of 
fusion protein was induced with O.lmM IPTG, when the ODeoo reached 0.5.
Harvested bacteria were resuspended in 10 mL STE (lOmM TRIS pH=8.0,150mM 
NaCl, ImM EDTA) supplemented with Img lysozyme. After 15 min 5mM DXT, 
0.2mM PMSF, 1.5% N-laurylsarcosine were added and the bacteria sonicated for 
approximately 3x20s. The fusion protein was purified on a gluthathione colunm 
(Pharmacia, Sweden), washed and eluted with 20mM gluthathione according to the 
manufacturer’s instructions. Before immunisation the fusion protein was dialysed 
against PBS. Three rats were used for immunisation. Each animal was injected sc four 
times in all, once every other week, with lOOpg/rat/immunisation. The first 
immunisation was supplemented with Freunds incomplete adjuvans.
Immunohistology: 2 x 10  ^ CSML-0 or CSML-100 cells were injected sc into 10- 
week-old mice. 8-12 weeks later the tumour was excised, fixed in 4% formaldehyde, 
embedded in paraffin and slides were prepared. The paraffin-embedded tissue were 
rehydrated, microwaved in 0.01 M Citrate pH 6.0 for 2 x 5 min, and incubated in 1% 
H2O2. Primary antibody incubation was done for 60 min using anti-cystatin C polyclonal 
antibodies diluted 1:200 in 10% foetal calf serum. Secondary antibody goat-anti-rabbit 
(P448, DAKO, Denmark) was diluted 1:100 in 5% normal mouse serum and incubated 
for 30 mirL After incubation the slides were rinsed and coloured with diaminobenzidin 
for 10 min.
Im m unocytochem ical staining: Cells were washed with PBS and fixed with 1:1 
mclhanohacetonc. Primary (anii-E30 serum) and secondary (horseradish peroxidase 
labelled goat anti-rat, DAKO, Denmark) antibody were added sequentially for 1 hour in
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PBS plus 10% PCS. Colour was developed with 3-amino-9-ethylcarbazol (Sigma, USA) 
in 15mM HAc, 35mM NaAc and H2O2
Protein localisation: This method was ad^ted from (148). One 10 cm dish 100% 
confluent CSML-100 cells (sq)p. 1x10  ^cells) were washed three times in PBS without 
calcium and magnesium, harvested mechanically and pelleted. The pellet was dissolved 
in 250pL buffer A (20mM HEPES (pH=7.2), 50mM KCl, 3mM MgCb and 0.25M 
sucrose) and mixed with 250pL buffer A supplemented with 0.2% Triton X-100, 
incubated one minute at room temperature and pelleted at 316g for four minutes. The 
Triton X-100 soluble fraction was saved (the membrane and cytosol fraction), the pellet 
resuspended in 250pL buffer B (20mM HEPES (pH=7.2), 50mM KCl, 3mM MgCb and 
ImM CaC y, mixed with 250pL buffer B supplemented with 0.2% NP-40 and 
homogenised for 5 minutes. The solution was pelleted for 5 minutes at 700g resulting in 
the NP-40 soluble fraction (the cytoskeletal fraction) and the pellet (the nuclear fraction). 
The three samples were tested in a Western blot as described.
Transfection: CSML-0 or CSML-100 cells were cultured in DMEM supplemented 
with 10% PCS. Cells were collected after trypsin-EDTA treatment, washed twice with 
PBS and used for electroporation. For each transfection lOOpL containing 1-2x10^ 
cells and lOpg pRc/CMV-10 or pRc/CMV-11, carrying the neomycin resistance gene, 
were electroporated at 250V and 250pFd using Bio-Rad electroporation system. Cells 
were plated directly in 5 96-well dishes. Sixteen hours after electroporation selection 
of transfected cells with G418 was commenced and continued for three weeks.
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3. R esu lts
Cloning genes differentially expressed in metastatic and non­
metastatic tumour cell lines
Three mammary adenocarcinoma cell lines were used in DD to identify genes 
putatively involved in the metastatic process. They were CSML-100 (metastatic to the 
lungs), CSML-0 (originating from the same tumour as CSML-100, but non­
metastatic) (136) and VMR-Li (metastatic to the liver and lungs) (137). For the DD
we used 32 upstream arbitrary 10-mer 
primers (Table 2.1) and one anchoring primer 
(TilAG). The reactions were repeated 
(reverse transcription and PGR) and 
reproducible bands differing in expression 
among the cell lines, were excised. Patterns 
o f gene fragments were largely identical 
among the three cell lines (Fig. 3.1). The 
strands of the amplified DD-fragments were 
separated on the denaturing sequencing gel 
resulting in several bands on the gel. The 
appearance of these bands was explained 
partly by the tendency o f the taq-polymerase 
to add an extra adenosine to the 3’ end of the 
PCR-product and partly by differences in 
molecular weight and mobility in the gel of 
, the strands. When a non-denaturing gel was 
used these multiple bands from the same 
amplification product were eliminated (data 
not shown). The separation of strands was
Figure 3 .1 : Identification of cDNA- 
fragments differentially expressed in DD in 
metastatic versus non-metastatic cell lines. 
Shown are the DDs carried out using 
downstream prim er CATn and upstream 
prim er 8, 9,13 and 14 in lanes 1-4 
respectively. The candidate cDNA- 
fragments (numbered), reproducibly 
differentially displayed, were excised.
5 5 0 -
5 0 0 -
4 2 0 -
2 5 0 -
200-
1 5 0 -
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more pronounced for the smaller fragments in the better separating part of the gel. A 
total of 56 fragments were selected for further analysis. The selected fragments were 
100% successfully PCR-amplified using the same conditions as used during the DD 
(Fig. 3.2). The sizes o f the selected DD-fragments ranged from 90-600 bp and 
corresponded to the sizes of the PCR-fragments. Except for fragment 50 a single band 
was amplified in the preceding PCR of the fragments extracted from the gels. The 
upper band of fragment 50 corresponded in size to the excised fragment.
tT  <n
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 M 41 42  43  50 51 52 53 54
Figure 3.2: PCR amplification of DD fragments. A selection of fragments excised from the sequencing gel. 
The fragments (number of fragment stated below the gel) were eluted from the sequencing gel, PCR 
amplified under the conditions used during the DD and separated on a 2% agarose gel. The m arker 
(M) is a 110 bp ladder. The picture is shown as a negative to facilitate printing and improve visibility.
The amplified fragments were labelled by either PCR or random priming and used as
probes for Northern hybridisation. At this stage, 31 of 56 fragments were selected for
further analysis (Fig. 3.3 and Table 3.1). While differential expression in some
instances was obvious (i.e. fragment 2, 3, 4, 10, 15, 18, 19, 21, 23, 30, 32, 42, 44, 46,
51), others were more subtle (i.e. fragment 5, 7, 9, 13, 14, 31, 35, 54 and 55).
Evaluation o f the results of the Northern blot hybridisation was complicated by
occurrence of several bands in each hybridisation. Over exposure of a DD-gel
revealed radioactivity on all positions in the gel. It would therefore be surprising if the
excised fragments were pure. These impurities thus resulted in background
hybridisations obscuring identification of differentially expressed genes. Only three of
the selected fragments hybridised with low or no background detecting differences in
gene expression (Fig. 3.3: fragments 18, 21 and 42), 28 were selected in spite of a
background signal (Fig. 3.3, the rest), 10 failed to show any signal, while there was no
difference in expression among the three cell lines for the remaining 15 fragments
(data not shown).
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Figure 3.3: Secondary screening of 31 selected and reamplified fragments against totalRNA from CSM L-100, VM R- 
Li and CSM L-0. O f the 56 excised fragments differential display 31 of these could be detected in Northern blotting 
with a possible differential expression. App. 10 pg of RNA from the specified cells were loaded pr lane.
24
The 31 fragments selected on the basis of the initial Northern blot hybridisations, 
were cloned, labelled and used in a second round of Northern blot hybridisation (Fig. 
3.4). The positive clones (from 95 to 536 bp long) were sequenced and a search for 
homology was made in the European Molecular Biology Laboratory (EMBL) 
database using the FASTA and/or BLAST sequence alignment programs (homologies 
are stated in Table 3.1). The pattern o f expression found in the primary Northern blots 
generally corresponded to the pattern found in the cloned fragments in the secondary 
Northern blots. However, the Lamin C homologous clone 15 had an expression 
pattern not detected in the primary Northern blots of these two fragments (Fig. 3.3 and 
Fig. 3.4). This difference could be explained by for example impurities in the band 
excised, aerosol mixing of samples before PCR-reactions, overexpression of 
competing signals in the primary Northern blot hybridisation leading to cloning of an 
otherwise undetected gene fragment. Also, the expression patterns of the isolated 
clone 32 were unanticipated. In some instances (fragment 17, 23 and 44) a 
differentially expressed gene was convincingly detected in the primary Northern blot, 
but the corresponding gene fragment never cloned.
The cloned fragments were tested in Northern blot analysis against CSML-0, CSML- 
100 and VMR-Li. The potentially non-metastasis related genes collagen XI a l ,  NN18 
(clone 18-4), MMTV and PACE4 were found mainly in CSML-0 cells, with small 
amounts o f MMTV and PACE4 in VMR-Li cells (Fig. 3.4). The potentially 
metastasis related genes Cystatin C, Lamin C, Ly-6A/E, NN9 and NN32 were found 
in CSML-100 cells. While Ly-6A/E expression was confined to CSML-100, Cystatin 
C expression was also seen in CSML-0. Lamin C, NN9 and NN32 were 
overexpressed in the two metastatic cell lines with low amounts detected in CSML-0 
(Fig. 3.4). Though the GAPDH labelling of the filter used for clone 21 (Ly-6A/E) 
showed, that it was not properly balanced, these data were confirmed (Fig. 3.6). The 
data for the cloning of fragment 30 is presented later.
The identified sequences were aligned with homologous sequences using Bestfit or 
Gap from the GCG-package (Fig. 3.5, mismatches depicted in reverse colours). We 
found that o f 17 analysed fragments, five contained sequences corresponding to 
MMTV, four corresponded to the Lamin C gene, four were homologous to other
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known genes (PACE4, Cystatin C, Collagen XI al and Ly-6A/E), three were 
homologous to previously published expressed sequence tags (ESTs) and one novel
19-6 
MMTV ♦
MMTV
i l |  
8 8 ; 3 8 1
Lamin C
# # #
35-1
C y sta tin  C
C oH agen XI %
LV-6AÆ
NN32 -►
Figure 3.4: Nine different fragments displaying differential expression were cloned. The nine 
fragments with a reconfirmed differential expression pattern as shown in Northern blotting. 
Below each filter a corresponding GAPDH hybridisation as control of RNA loading. App. 10 
pg of RNA was loaded p r lane. Sequencing and EMBL database searching revealed sequence 
homology to published genes. Arrows depicts differentially expressed genes indicating the 
possible homology.
DNA-fragment (Fig. 3.5 and Table 3.1) (data for fragment 30 is shown later). The 
EST-fragments, recognised by clone 18-4 and clone 9-1, were isolated from brain and 
mammary gland, respectively. Ignoring the mismatches in the primer regions and the 
previously unpublished 3’-stretches, four o f the clones (clone 5-1, 21-o, 42-1 and 9-1) 
completely matched their homologue, while two clones (clone 35-1 and 46-4) 
contained a single mismatch. Mismatches in clone 19-1 (MMTV) recognising the 5’ 
long terminal repeat probably arose from comparing different substrains of the virus, 
while clone 46-4 (PACE4) and clone 18-4 (NN18) were aligned to rat sequences. Due 
to the low fidelity of the taq-polymerase mismatches could also occur during PCR.
All bands were found to contain the expected upstream and downstream primer 
sequence at the 5'- and 3'-ends underlined in figure 3.5. The 5’-primer site contained 
one or two mismatches compared with the known mouse sequence. However, in the
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clone 19-6 (MMTV) Length: 492 bp
1 TCQQTCATAQ TACTTATGAT TTTCCCCÇTT gTTTTCCAGT GCflTTGCGAA GAGCCTTGAC CAAOTGCAGT CAGATCTTAA CGTGCT
101 AAAAAGGGGG AAATGCCGCG CCTGCAGCAG AAATGGTTGA ACTCCCGAGA GTGTCCTACA CQTAGGgGAG AAGCAGCCAA GGGGTT
201 ACGACCgGTC T g g A C g A g  CGGATGAGCC CATCAGACAA AGACATAjTC ATTCTCTGCT GCAAACTTGG CATAGCTCTG CTTTGC
301 GAAAGTTGCG GTTCGTGCTC GCAGGGCTCT CACCCTTGAT TCTTTTAATg ACTCTTCTGT GCAAGATTAC AATCTAAACg ATTCGG
401 CTCCTGgGGC AAGGACCACA GCCAACTTCC TCTTAgAAGC CgCGACTTTG TCCTTCAGAA ATAGAAATAA GAATGCTTGC TAAAAA|
C lo n e  5-1 (Lamin C) Length: 183 bp
1 ACAATGAGGA T|GSCQKCGSQ~a|ATGGAGAAG AGCTCCTCCA TCACCACCGT GTGAGTGGCA GCCGCCGCTG AGCCCA
101 CCCTGCCAGC CTAGGGCAGC TCTCCCACCT CCATGCCAAA GTCTTTTCAT TAAAGAATGT TTTGGAATGC CgAAAAAAAA AAA
clone 21-0 (Ly-6A/E) Length: 536 bp
1 QQTACTAAGG TCAATGTGAA GACTTCCTGT TGCCAGGAAG ACCTCTGCAA TGCAGCAGTT CCCAATGGAG GCAGCACCTG GACCAT
101 TGTTCAGCCT GAGCTCAGTC CTCCTGCAGA CCTTGCTCTG ATGGTCCTCC CAATGACCTC CACCCTTGTC CTTTTATCCT CATGTG
201 GGAGCCCTCT AGTGATGAAT TATGAGTTAT AGAAGCTCCA AGGTGGGAGT AGTGTGTGAA ATACCATGTT TTGCCTTTAT AGCCCT
301 TGCTCTAATC CTCTCTAGGG CTTTCAAGTC TGTACTTCCT AGAATGTCAT TTTGTTGTGG ATTGCTGCTC ATGACCCTGG AGGCAC
401 GAAGAGGCAG AATTCCAAGG TATTATGCTA TCACCATCCA CACATAAGTA TCTGGGGTCC TGCAATGTTC CCACATGTAT CCTGAA
501 GTCCAATAAA CCCTTTGTTC TCCCgAAAAA AAAAAA
clone 42-1 (Collagen XI alphal) Length: 178 bp
1 Ba t c t a a c c g g a g a g g a t t a t g a t g t c c a g a g a a a c a c t t c c g a g g a t a t t c t g t a c g g g a a c a a a g g a g t a g a c g g c a g g g a t t c
101 ATGGAGATTT AGGTGAATAT QATTTTTATG AATACAAAGA ATATGAAGAA AGGACTACGA CCTCCCCTAA ™  =
clone 46-4 (PACE4) Length: 156 bp
1 p ^PTnA|gTg TAATGTGTTT GTCTTGTCAC CTGTA^TGG^CAAGGACTCA GCTGTTGTCT GTTGAATCCA CACTTCAAAT AAGAAA 
101 CTAATGTTAA CCCTGAGgggggggggggggggggggggggggggggU^^^-^^^^
clone 35-1 (Cystatin C) Length: 393 bp
1 jAHCAAGTCC CAGACAAATT TGACTGACTG TCCTTTCCAT GACCAGCCCC ATCTGATGAG GAAGGCACTC TGCgCCTTCC AGATCT
101 AAAGGCACAC ACTCCCTGAC AAAATTCAGC TGCAAAAATG CCTAAGGGCT GAGTCTAGAA GGATCATGCA GATTGTTCCT TACTTG
201 AQTGTTTCAT CTCGCAGAAG GGTGCTCCGG CTCTGGAGGG CACCGCCAGT GTGTTTGCAC CAGGAGACAG TAAAGGAGCT GCTGCA
301 ATCTGAACAG CTGTCCCCTG GCTCCACTCT TCTTGCAGTA CCTATCATGC CTTGCTCAAT TAAAAjAAAAA ACTCCTTTGG CTAAAA
clone 9-1 (NN9) Length: 309
1 gTTTCTACCC AGGAGATATC TTATATTTGG AAAATGTCTG CCTCTCCAAA TAAATATGTG ATTAATAAGC CATATCAGAG TTTAAG
101 CCCCTCCAAA AACCAAGTAT TTTGCATATG ATTGATTTTA GAAAGATTTT GAAGCTGGGG TTTATCTGTG TAATGAAGAC CAGATT
201 TGCATTTGTA ATTTTCAAAT GAAATTTCCT ATACGATTAT TJ
301
AAATAAAGT GTTGTTTTGC CTTGTGGTTT ATTAAAAACT TAAAAT
C lo n e  18-4 (NN18) Length: 111 ___ _
1 nçg ^ ^ G g G ^^AgAAGGGT AGGGCCAGGT GTTCTGTgCT TGGGAATGTA GGGCTATCCT TACgTGTGTA AATAAACCCT gjggggg
101
clone 32-9 (NN32) Length: 95
1 AGCTACTGAC ACACATGAAC TTTCACACAC AAATAAATGA CTATATATGA TAAAATTAAG GAGAAAAAAA TTCTCCCTTG TGCTAA
Figure 3.5; Genes identified using DD from metastatic or non-metastatic tum our cell lines. Nucleotide 
sequence of the 9 differentially expressed fragments. Clones homologous to sequences in the EMBL- 
database were compared to corresponding known genes. The comparison revealed several mismatches, 
deletions or unknown 3’-sequences indicated in reverse colours. Prim er sites are underlined, the box 
depicts an upstream  prim er site in Lamin C better than the one used. Sequences were compared to 
other mouse sequences except clone 46-4 and 18-4 compared to ra t sequences.
Lamin C sequence the 5’-primer detected a site of only four matching nucleotides.
Curiously, though the PCR technique has a tendency to favour shorter amplification
products, the Lamin C sequence contained a better primer recognition site, 21 bases
downstream of the utilised primer site (Fig. 3.5, boxed, 8 matching nucleotides). None
of the 3’-end sequences in the EMBL database matched the complement of the
downstream primer sequence CTAn found in the cloned fragments. This variation in
site of polyadenylation could indicate that the DD-selected 1/12 of the transcripts did
not represent 1/12 of the transcribed genes. The fragments homologous to the MMTV
gene and the Collagen XI a l  gene corresponded to an internal part of the transcript
corresponding to a 5 ’ -CTAAAAATTATAT-3 ’ and a 5’-CTAATGAAGAATT-3
stretch inside the RNA, respectively.
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Table 3.1:
The 31 selected fragments differentially expressed in the CSML cell line system.
Fragment Primer Fragment DD Clones w/ Homology Approx. s ize
# Up Size Expression diff. expr. of transcript
2 1 250 bp CSML-0 + MMTV 10 kb; 4 .5  kb
3 1 200 bp CSML-0 + MMTV 10 kb; 4.5 kb
4 1 190 bp CSML-0 + MMTV 10 kb; 4.5 kb
5 1 180 bp CSML-100VMR-U + Lamin C 2.0 kb
7 1 160 bp CSML-100
9 3 300 bp CSML-100 + EST(AA427021) 4.5 kb
10 4 320 bp CSML-OA/MR-Li
13 6 300 bp CSML-0
14 8 400 bp CSML-OA/MR-Li
15 8 240 bp CSML-100 + Lamin C 2.0 kb
16 8 200 bp VMR-Li + Lamin C 2.0 kb
17 8 120 bp CSML-0
18 8 110 bp CSML-0 + EST(W 71785) 2.0 kb
19 9 450 bp CSML-0 + MMTV 10 kb; 4 .5  kb
20 9 250 bp CSML-0
21 10 500 bp CSML-100 + Ly-6A/E 0.9 kb
23 10 115 bp CSML-0
28 E 190 bp CSML-100A/MR-Ü + Lamin C 2.0 kb
30 E 118 bp CSML-100A/MR-Ü + E30*’^ 1.4 kb
31 E 100 bp CSML-O/VMR-Li
32 E 90 bp CSML-100 + No match 0.5 kb
35 14 400 bp CSML-100 + Cystatin C 0.7 kb
42 21 180 bp CSML-0 + Collagen XI a l 7.0 kb
44 21 100 bp CSML-100
45 23 310 bp CSML-0 + MMTV 10 kb; 4 .5  kb
46 23 150 bp CSML-0 + Rat PACE4 4.2 kb
47 23 110 bp CSML-0
51 AP2 600 bp CSML-0
54 AP3 220 bp CSML-0
55 24 400 bp CSML-0
The protein names of the homologous sequences are mentioned. Sequence data are from 
mouse except ra t PACE4 and ra t EST(W71785).
A new gene described here.
Expression in mouse cell lines with varying metastatic potential
To further investigate the possible significance of the isolated genes in tumour 
progression, we compared transcription of six of the genes to the expression pattern of 
known metastasis-related gene (i.e. E-cadherin) using a panel of 14 mouse cell lines 
o f varying tumourigenic and metastatic potential. The genes identified in this study, 
but not tested in this panel were: MMTV, since its involvement in progression is 
believed to be secondary, possibly via activation of non-MMTV related genes during
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integration into the genome (149), and clone 18-4, since the CSML-0 hybridisation 
from this clone faded during the experiment. Trying to hybridise this clone to the 
panel o f cell lines gave no signals. The panel o f cells consisted of four related 
adenocarcinoma cell line systems, the previously mentioned VMR and CSML, plus 
M Tl (138) and RAC (139) systems and three additional cell lines, Linel(141), LL-
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Figure 3.6: Northern blot analysis of probes corresponding to PACE4, Collagen XI a l ,  E- 
cadherin, Cystatin C, Lamin C, Ly-6A/E, clone 9-1 and clone 32-9 in a panel of 14 mouse 
tum our cell lines. Metastatic (+), non-metastatic (-) or not assayed (na) in an assay using 
either subcutanous (s.c.) or intravenous (i.v.) injections (151). Sufficient amounts of RNA 
vyas prepared and adjusted according to (120) and used for loading several gels with 10 pg 
per lane. A sample EtBr-stained gel is shown.
Met (142) and 10T!6 (143). The panel contained two non-tumourigenic cell lines 
(10T!4 and RAC311C), three non-metastatic cell lines (VMR-0 p9, CSML-0 and 
RAC 1 OP), one cell line metastatic in a spontaneous assay only (MT1TC3), four cell
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lines displaying metastatic behaviour in the experimental assay only (VMR-0 p25, 
M Tl TCI, RAC34E and RAC5E) and five metastatic cell lines metastatic in both 
assays (VMR-Ly, VMR-Li, CSML-100, Linel and LL-Met). The VMR-0 cells 
became experimentally metastatic when passaged from p9 to p25.
As can be seen, expression o f PACE4 mRNA closely resembles the expression 
pattern of E-cadherin since VMR-0 p9, VMR-Ly, VMR-Li, CSML-0 and MTl TCI 
all express both genes (Fig. 3.6). There are two discrepancies: E-cadherin is expressed 
in RAC 1 OP, while barely detectable amounts of PACE4 mRNA are found in IOTV2 . 
The gene coding for Collagen XI a  1 is transcribed only in the E-cadherin expressing 
cell lines, VMR-0 p9, VMR-Ly and CSML-0, in the latter in an alternatively spliced 
form as shown (Fig. 3.4 and 3.6) (150).
The genes upregulated in CSML-100 cells were transcribed in most of the cell lines. 
The transcription of the gene coding for Cystatin C was suppressed in VMR-0 p9, 
VMR-0 p25, VMR-Li and CSML-0 and present in all other cell lines. In the VMR 
cell system expression of Cystatin C was elevated in the VMR-Ly, in the CSML cell 
system CSML-100 expression was increased, it was upregulated in the highly 
metastatic cell lines Line 1 and LL-Met, while no variation in expression could be 
detected in the M Tl and RAC cell line systems.
Transcription o f the gene encoding Lamin C was found in all the cell lines at variable 
strength. However, it was upregulated in cell lines metastatic in the spontaneous assay 
and in VMR-0 p25.
Ly-6A/E expression was confined to metastatic cell lines, in that VMR-0 p25, VMR- 
Ly, CSML-100, LL-Met, MT1TC3, RAC5E and RAC34E express and the non­
metastatic CSML-0, VMR-0 p9, and RAC 1 OP do not. Lack of expression in Linel 
was shown elsewhere (152).
The two unknown genes also detected transcripts in all cell lines. Increased 
expression of NN9 transcripts was found in the metastatic cell lines of the VMR and 
CSML cell line systems, and with strong expression in LL-Met cells. NN32 displayed
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increased expression in most of the cells capable of spontaneous metastasis to the 
lungs, i.e. VMR-Li, CSML-100, Linel, LL-Met and MT1TC3. Also, expression was 
elevated in the non-tumourigenic lOTK and RAC311C. An attempt was made to 
isolate full-length NN32 from a CSML-100 cDNA library. However, all twelve 
potential full-length length clones obtained had no homology to NN32. Instead they 
were homologous to galectin-1 (data not shown).
In general the genes upregulated in CSML-0 had a tendency to be expressed in VMR- 
0 p9 and M TITCI, and not expressed in VMR-0 p25, CMSL-100 and MT1TC3. As 
opposed to this expression pattern, the genes upregulated in CSML-100 tended to be 
expressed in Linel, LL-Met and VMR-0 p25 as well as in the two non-tumourigenic 
cell lines, but downregulated in CSML-0 and VMR-0 p9. Only in the case of Ly-6A/E 
did the RAC cell lines show differential expression of an identified gene.
Analysis of Cystatin C by Western blot and immunohistology
Since, the expression o f Cystatin C in Northern blots was seen to correlate with the 
metastatic phenotype, the correlation of expression of protein using Western blot 
analysis and immunohistology was analysed. Cystatin C was detected in in vitro culture 
of CSML-100 cell lysates with the expected size of 14kDa, while the CSML-0 cells 
displayed only low amounts of the protein (Fig. 3.7A). Basically the protein expression 
corresponded to the level of mRNA detected, but lower than expected protein levels 
were seen in the MTl TCI, RAC5E and RAC 1 OP cell lines. Immunohistological 
examination of Cystatin C expression in tumours originating from CSML-0 and CSML- 
100 cells revealed increased overall staining of Cystatin C in the CSML-100 tumour as 
compared with the CSML-0 tumour (Fig. 3.7B).
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Figure 3.7: Distribution of Cystatin C protein in cell lines and tum our tissue. (A) Detection of 
cystatin C in 14 cells lines of different metastatic potential by Western blot analysis. Total 
lysate of app. 10,000 cells were separated on a 15% SDS-PAGE gel, blotted, labelled and 
stained using ECL. Ponceau S staining of the filter was used to control the amounts of protein 
blotted to the memebrane. Abbreviations as in Fig. 3.3. (B) Immunohistology using anti- 
cystatin C polyclonal antibody. Sections of tumour from metastatic CSML-100 cells and from 
non-metastatic CSML-0 cells were used for immunohistology. 40x times magnification shown. 
The tum our arising from metastatic cells reacts intensively with the antibody.
Due to the hybridisation pattern of clone 30-8 to CSML-100, VMR-Li and CSML-0 in 
Northern blot analysis further investigations of this clone were carried out.
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Figure 3.8: Identification and RNA expression of fragment E30. (A) A DD carried out using downstream 
prim er CAT,, and upstream prim er E. The fragments depicted by the arrow were excised. Size in bp is 
indicated to the left. (B) The fragments were cloned and retested showing differential expression in Nor­
thern. A GAPDH-hybridisation is shown below. (C) Transcription of E30 was tested in Northern against 
the panel of cell lines introduced in Fig. 3.6. The size of the E30 recognised transcript was app. 1.4 kb. 
The upper blot shows hybridisation with E30 alone. Below a stronger hybridisation also containing 
transcription factor AlO of 1.8 kb as control for size and presence of RNA. The 18S band of the EtBr- 
stained gel is shown below. (D) Northern blot of E30 hybridising to RNA from embryos. PolyU-hybri- 
disation is shown below. E30 was detected at 10.5-18.5 dpc. App. lOpg/lane of total RNA were loaded.
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Com plete coding sequence of clone 30-8
Due to potential patenting rights the sequence is not stated in the text, which unfortunately makes description and review  
less practical. Please excuse the inconvenience.
Figure 3.8 depicts the isolation and RNA expression pattern of fragment 30. Fragment 
30 was isolated in the same round of DD as described above. The 118 bp fragment 
was expressed in the two metastatic cell lines CSML-100 and VMR-Li (Fig 3.8A). 
This expression pattern was confirmed by Northern blot analysis prior to and after 
cloning (Fig. 3.4 fragment 30 and Fig. 3.8B).
Northern blot revealed expression in several metastatic cell lines (Fig. 3 .8C). Thirteen 
of the cell lines in the panel of cells presented previously (Fig. 3 .6 and above) was 
supplemented with the Miller cells: 66CL4, 67NR, 168FARN, 4T07, 4T1 isolated 
from the same adenocarcinoma (140) and the non-tumourigenic, fibroblast cell line 
NIH3T3. The metastatic ability of the cell lines is depicted in figure 3.8C (151). A 1.4 
kb transcript was found in the metastatic VMR cells, CSML-100, LL-Met, RAC34E, 
RAC5E and 66CL4, but not in the non-metastatic CSML-0, 67NR and 168FARN, and 
the non-tumourigenic NIH3T3 and IOTV2 fibroblast cell lines. Though expression was 
found in non-metastatic RAC 1 OP and VMR-0 p9 and no expression was found in the 
M Tl and 4T cell lines these data encouraged further investigations into the potential 
role of E30 in tumour progression.
To investigate expression of E30 during embryogenesis. Northern blot analysis was 
performed using total RNA from embryos of days 10.5 to 18.5 of pregnancy (Fig. 
3.8D). The E30 transcript was detectable during a period extending from day 10.5 to 
day 18.5 of mouse embryogenesis. At stage 15.5 dpc transcripts were present in both 
the head and back of the embryo (Fig. 3.8D). The faint signals obtained at day 10.5, 
16.5 and 18.5 was due to smaller amounts of RNA loaded as judged from the polyU 
hybridisation.
Sequence information
Sequencing and database analysis did not reveal relation to any complete coding 
sequence, but only to several ESTs. ESTs are short sequences obtained sequencing 
PCR-fragments from different cDNA-libraries with the purpose o f mapping the
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expressed genes in a given sample. The sequence and its origin are the only 
information available. The 3 ’ end lacked a conventional polyadenylation signal like 
AATAAA or ATT AAA (153). However, alternative sequences like TATAA,
GATAA or AATTA resembling polyadenylation signals were all situated less than 25 
bp from the non-poly-A part of the 3 ’ end. The ends corresponded to primers used.
Expression in the embryo (Fig. 3.8D) and in uterus of pregnant mouse (data not 
shown) validated further analysis of E30, since specific cells in these organs 
(trophoblast invasion o f the uterus and migration of mesenchymal cells during 
embryogenesis) are models for metastasis. In order to obtain the complete coding 
sequence, a X-phage cDNA library derived from the metastatic CSML-100 cell line 
was screened using fragment 30. When screening 300.000 plaques, one clone was 
found with a 3’ end matching fragment 30. This clone contained an 1137bp E30 
fragment and 1700bp o f 5’ AlO transcription factor sequence separated by an EcoRI-
site. The AlO transcription factor
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Figure 3.9: Orfs computed in the potentially full length 
cDNA-clone of E30. (A) One large orf in reading frame 
2 of the cDNA was found with an initiating methionine 
coding ATG at position 23 and a terminating TGA at 
position 1036, potentially producing a 338 aa protein. 
There are several stop codons preceding this first stop 
codon. Line up and line down depicts methionine and 
stop codons, respectively. (B) The initiating ATG is 
surrounded by a sequence closely resembling the 
Kozak sequence predicting ATG-codon use. The 
significant nucleotides of the Kozak sequence are 
compared to the sequence of E30 with lines indicating 
homology.
was shown to be ubiquitously 
expressed in the mouse 
carcinoma cell lines (Fig. 3.8C). 
Data processing revealed one 
large open reading frame (orf) in 
frame 2 of the E30 sequence 
(Fig. 3.9A). This orf has a 
potential ATG translation 
initiation sites, one o f which is 
situated at nucleotide 23 and 
ending with a stop codon at 
position 1036 (followed by two 
more within the next 12 
nucleotides). This orf should 
then code for a protein of 338 aa 
corresponding to a calculated
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molecular weight o f about 39kDa. The translational initiation site conformed to the 
rules set out by Kozak (154), since seven out of nine important nucleotides match this 
sequence (Fig. 3.9B).
Structure of E30 protein
Analysis of the structure of the putative protein did not reveal any specific traits. For 
instance no obvious signal or transmembrane sequence was found in the Kyte & 
Doolittle hydropathy plot (Fig. 3.10A). The composition of the protein was consistent 
with a “normal” protein, except for approximately twice as many tryptophan residues 
(2.4% as opposed to 1.3% in an “average” protein) five o f them situated within the 
initial 51 N-terminal amino acids. Since tryptophan often participates in ligand- 
receptor bindings this could indicate an adhesion function of the N-terminal region. 
The putative protein contained five potential phosphorylation sites, usable by Protein 
kinase C, six usable by Casein kinase 2 and two potential N-glycosylation sites. 
Testing the sequence for known protein motifs using the MOTIF command in the
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Figure 3.10: Hydropathy plot and composition of E30. (A) The hydrophobicity and 
hydrophilicity of E30 protein was calculated using the Kyte & Doolittle plot with a window 
of seven aas. No obvious transmembrane region or signal sequence was found. The 
composition of E30 protein was listed (B) revealing an “average” protein with only number 
of tryptophanes notably elevated. The theoretical molecular weight was calculated to be 
38.6kDa and the net charge -8.
GCG package identified no additional known protein motifs. When allowing for one
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mismatch, only six targets where identified, none making sense upon closer 
investigation (lacking a vital amino acid, positioned wrongly, prokaryotic motif only 
etc.). Allowing an additional mismatch did not reveal meaningful homologies either.
Homologies of E30 cDNA to mouse ESTs
A search for homologues of E30 was performed, comparing the sequence with 
sequences in several databases. No obvious homologies were found in the databases 
consisting of complete coding sequences. However, a number o f EST fragments in the 
dbest-database displayed homology to E30 (Fig. 3.11). A group of mouse EST- 
ffagments, almost identical to E30, was found in placenta, blastocyst, foetus at various 
days post coitum (dpc), T-cells, thymus, lymph nodes, mammary, kidney and heart, 
indicating expression o f the gene in these tissue. This was in correspondence with the 
Northern blot of embryos at day 10.5 to day 18.5 (Fig. 3.8D).
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Figure 3.11: A representative selection of mouse EST fragments with homology to ESQ. A search in the 
dbest database revealed 23 DNA fragments > 99% identical to E30 from several different tissues covering 
the majority of the gene. The arrows depict the length of the fragments compared to E30 with the 
originating source indicated below. Dpc indicates days post coitum. The coding region of E30 is boxed.
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Homologies of E30 cDNA to human and C. elegans ESTs
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Figure 3.12: Non-murine ESTs. Five EST homologues isolated from human fetal heart (Hum fet 
heart), human liver (hum liver), human small intestine (Hum intestine), Ju rka t T-cells or from 
C. elegans as revealed by searching the dbest-database. Symbols and layout are as in Figure 
3.11. Relationship to E30 is in descending order (nearest homologues are closest to E30) and 
indicated as % identity at nucleotide level.
Also homologies to four human and a single C. elegans sequence were discovered, 
again in sequences from dbest (Fig. 3.12). The EST-fragment isolated from the Jurkat 
T-cell line was the closest relative being 77%/75% identical on the DNA level/amino 
acid level assuming the reading frame with the greatest matching score aligned using 
the GAP-program from the GCG-package. The remaining fragments were discovered 
in human small intestine (46%/85%), human foetal heart (65%/55%), human liver 
(48%/45%) and in C. elegans (46%/40%) with a DNA homology/protein homology as 
indicated in parenthesis. The high protein homology of the fragment from human 
small intestine is due to a highly identical short C-terminal homology of seven amino 
acids with only one mismatch, while the lower homology of the corresponding DNA 
sequence is due to the low pressure o f conservation on untranslated 3’ ends. The low 
homology of the putative protein from human liver can be improved to 54% (amino 
acid identity) if  only the C-terminal 36aa were used for comparison. Whether the 
human homologous fragments represent one gene or several is not known. An attempt 
was made to isolate the DNA-sequence between the 5’ end and 3’ end fragments with 
an upstream primer matching the foetal heart fragment and a downstream primer 
matching the fragment from Jurkat. This attempt was unsuccessful (data not shown), a 
result which could be interpreted as pointing to the existence of more than one human 
gene matching E30. The overlapping fragments o f EST-sequence from human small 
intestine and Jurkat cells are 98% identical (DNA). However, the overlapping 
fragments o f EST-sequence from human liver compared to human foetal heart is only
38
47% identical on DNA-level and 59% on amino acid level providing more compelling 
evidence o f the existence o f more than one human gene homologous to E30.
Cysteine and tryptophan residues are often conserved among species in homologous 
proteins. The potential protein contains seven cysteine residues (Fig. 3.1 OB), and 
when comparing with the non-murine sequences, four appeared conserved. The 
tryptophan residues were generally less conserved, with the only exception, a 
tryptophan in the 3aa-sequence SerPheTry as the most highly conserved sequence 
when comparing human, mouse and C. elegans.
Production of GST-E30 fusion protein
In order to produce protein for immunisation o f rats. Western blot analysis and 
immunohistology, a fusion protein was constructed. The GST-system was selected 
due to the ease of purification of fusion protein with gluthathione columns and 
experience for production o f polyclonal antibodies within the institute. The E30 
cDNA was placed into the pGEX-vector using an in frame EcoRI-site (Fig. 3 .13A) 
resulting in an inducible fusion protein construct comprising of Gluthathione-S- 
transferase N-terminally and E30 C-terminally spaced by 15 aa containing a Factor 
Xa site and seven aa arising from the otherwise non-coding 5’ end of the E30 gene. 
Expression of fusion protein was even seen before induction as a band after SDS- 
PAGE. Induction of expression led to the highest expression after three hours (Fig. 
3.I3B). Though, extensive sonication was performed only approximately 50% of the 
protein was soluble. The purified fusion protein had a size close to the predicted 
65kDa (Fig. 3.13B). Approximately I.6mg was purified from a 500mL culture 
induced for 3 hours.
Three rats were immunised once, boosted four times, sacrificed and the sera tested for 
reactivity against E30 by Western blot analysis containing cell lysates from CSML- 
100, CSML-0 and VMR-Li (Fig. 3.13C). While the immune serum from rat 1816 
showed reactivity against a protein o f the expected approximately 39kDa, this 
reactivity was less pronounced than serum from rat 1817, and the serum of rat 1818 
did not respond at all. Since the preimmune serum from 1817 contained reactivity 
against a protein o f approximately 39kDa, the serum from rat 1816 was used in all
39
AC
Rat#: 1816 1817 1818
T I
G
3
3cZJ
C /Î
CD
3
3
3
c3
U i '
CD
Q .
3
c/T
CO CO CO COCO CO
C *  1
Oh 1%h 3h
D
1 2
Opg/mL 3|jg/mL 30ug/mL
O O <
CO CO CO CO CO CO
Figure 3.13: Production of polyclonal antibodies against E30 in rats. (A) The complete cDNA sequence con­
taining the ATG-codon was inserted into the pGEX-30X-vector. The resulting fusion protein comprises the 
26kDa Schistosoma japonicum gluthathione-S-transferase (GST) part and E30. (B) Induction of fusion pro­
tein GST-E30 separated on a gel. Protein production induced with O.lmM IPTG in the stated amount of time 
and thereafter harvested and purified (lane 4) and used for immunisation. (C) Western hlot analysis of the 
activity of the immunised ra t sera to E30 protein. The reactivity of the sera (diluted 1:100) of three rats was 
tested against app. 10.000 lysed cells of CSML-0, CSML-100 and VMR-Li prior to immunisation and 
following three immunisations and a boost. Serum from rat 1816 was selected for further experiments.
(D) Blocking experiment performed to confirm the E30 reactivity. The activity to E30 was blocked using 
increasing amounts of purified fusion protein, from no fusion protein (hlot #1) to 3 pg/mL (hlot #2) to 30 
pg/mL (hlot #3). The suspected E30 protein is indicated with an arrow. Serum dilution was 1:200.
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further E30 immune experiments. The background o f this serum in Western blots was 
reduced when the dilution of the antibody was increased from 1:100 to 1:400.
To test the specificity of the obtained serum an inhibition experiment was performed 
(Fig. 3.13D). The reactivity against E30 seen in blot#l in figure 3.13D was blocked 
with increasing amounts of purified fusion protein from lane 4 o f figure 3.13B. 
Complete blocking of the specific binding to the protein of approximately 39kDa was 
observed after adding increasing amounts o f recombinant fusion protein (3pg/mLin 
blot #2 to 30pg/mL in blot #3) as seen in blot# 1-3.
E30 protein expression in tumour cell lines
To further elucidate the expression pattern on protein level the anti-E30 serum was 
tested against the panel of cells used in figure 3.8C using Western blot analysis (Fig. 
3.14A). Protein expression was highest in the metastatic CSML-100, LL-Met, RAC34E 
and RAC31 IE, low in VMR-Ly and VMR-Li, and not detectable in the non-metastatic 
CSML-0 and the non-tumourigenic 10T14 and NIH3T3. Protein expression was not 
detected in RAC5E in contrast to the Northern blot analysis showing transcription. 
Otherwise the data fi-om Western blot analysis confirmed the data fi-om Northern blot 
analysis (Fig. 3.14A).
Evaluation of the expression pattern in various tissue could imply a possible function 
and substantiate a potential role in metastasis. To investigate the presence of the E30 
protein in normal tissue of adult mice. Western blot experiments were performed with 
lysates from different organs. A protein o f approximately 39kDa was detected in all 
samples tested (i.e. liver, lung, kidney, testis, brain, heart, thymus and spleen) except 
for salivary gland (Fig. 3.14B). Expression in brain was found in a separate Western 
blot analysis (data not shown).
Fractionation of CSML-100 cells was used to investigate the localisation of E30 (Fig. 
3.14C). The cells were roughly fi-actionated into a cytoskeletal, a cytosolic and a nuclear 
fi-action. Firstly, the cytosol was extracted with 0.1% Triton X-100, while the structure 
was retained with sucrose. Secondly, the cytoskeletal fi-action was extracted with 0.1% 
NP-40 and calcium leaving the nuclear proteins in the pellet. E30 was detected in the
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Figure 3.14: Western blotting comparing E30 protein expression. (A) Western blot analysis of cell lysates 
from a panel of mouse ceU lines tested against anti-E30 serum. App. 10.000 ceUs/lane (adjusted 
individuaUy using Coomassie-staining of gels) were separated on a gel, blotted to a filter and tested 
against anti E30 serum diluted 1:400. A 39kDa protein was stained in the majority of the metastatic 
cells. (B) Western blot analysis of tissue lysates. The presence of E30 was shown in spleen, thymus, 
heart, testis, kidney, lung and liver. The absence of signal in brain and the low amounts detected in 
testis was due to bad protein transfer in this area. A second Western blot experiment showed amounts 
equal to the other tissues of E30 protein in brain and testis (C) Fractionation of CSML-100 cells localised 
E30 protein to the cytoplasma. CSML-100 proteins were fractionated as described. E30 protein was found 
in the cytoplasmic and cytoskeletal fractions. In general the proteins were separated on a 12% SDS- 
PAGE gel, hiotted and reacted with anti E30-serum (1:400 dilution).
cytosolic and cytoskeletal fractions, indicating that E30 was localised in the cytoplasm,
possibly interacting with the cytoskeleton.
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In situ hybridisation of E30 cDNA
E30 transcripts detected by Western blot analysis showed that the E30 gene was 
expressed in various tissue. To show E30 transcript distribution in more detail, in situ 
hybridisation experiments were performed on sections o f testis, uterus, spleen, 
thymus, brain, trachea, lung, oesophagus, stomach, skeletal muscle and decidua of 
day 8.5 and 16.5, including the placenta and all extraembryonic membranes.
In situ hybridisation of tissue
The strongest signal was observed in spleen and thymus. Even short exposition times 
evolved strong signals in both organs (Fig. 3.15A). E30 transcript was expressed at 
more modest level in the testis. Figure 3.15D shows an accumulation o f silver grains 
in the outer area of the seminiferous tubules. E30 signals were also detected in the 
epithelium and the lamina propria o f the oesophagus and the stomach (Fig. 3.15H). In 
contrast the tunica muscularis was negative. Similar results were obtained from the 
trachea, where both the columnar epithelium and the lamina propria stained positive 
(data not shown). No signal was detected in the skeletal muscle. The hybridisations 
corresponded to Northern (data not shown) and Western blot results detecting E30 in 
testis, thymus, uterus, embryonic tissue and placenta. However, no in situ 
hybridisations could be detected in lung and liver, though these tissue show 
expression using Western blot analysis.
In situ hybridisation in embryos
Data from ESTs and Northern blot experiments showed expression of E30 transcripts in 
embryo at several stages o f development. To investigate in more detail the expression 
of E30 gene during mouse embryogenesis in situ hybridisation experiments on sagittal 
sections o f day 12.5, 14.5 and 16.5 embryos were performed. At day 12.5 we detect 
the E30 transcript in the developing liver (Fig. 3.16A-C). At day 14.5 and 16.5
Figure 3.15: In situ hybridisation of the E30 gene in different tissues of the adult mouse. (A-C) Section of 
the thymus: medulla and cortex parts are shown. (A) Antisense hybridisation giving ubiquitous signal 
distribution. (6) Control hybridisation. (C) Hematoxylin-eosin(HE)-staining. (D-F) In situ hybridisation 
analysis of testicular tissue. (D) Antisense hybridisation detecting the E30 transcript in the outer layer 
of seminiferous tubules. (E) Sense hybridisation. (F) Antisense hybridisation of a seminiferous tubule at 
higher magnification. (G) The same region shown in F. (H J) Detection of E30 transcripts in stomach. (H) 
Antisense hybridisation detecting E30 transcripts in the mucosal layer. (I) Sense hybridisation. (J) HE 
staining. C, cortex; ge, germinal layer, lu, lumen; M, medulla; mu, mucosa; ow, outer wall; se, 
seminiferous tubules.
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Figure 3.16: In situ hybridisation analysis of E30 transcript expression during mouse embryogenesis 
(A C) Saggital section through the trunk of a 12.5 dpc embryo (A) Strong signal show the liver. (B)
Control hybridisation with E30 sense probe shows no signal. (C) HE-stained section; framed area is 
shown in (A). (D-F) Sagittal sections though a 16.5 day old embryo. (D) Showing upper part of the 
embryo with signals in the lung, skeletal muscle of the neck and muscle elements of the head. (E)
Dark field photomicrograph of an adjacent section to that in (D) hybridised with E30 sense probe show 
no signal. (F) HE-stained section of (D). 11, liver, Lu, lung; sk, skeletal muscle.
expression of E30 transcript was found in the developing lung and skeletal muscle of 
the neck and muscle elements of the head (Fig. 3.16D-F) but not in the liver.
In situ hybridisation of uterus and extraembryonic tissue
Expression of E30 transcripts in uterus of a pregnant mouse (data not shown) 
encouraged in situ investigation of this organ. The preparation from the uterus of 
pregnant mice includes the deciduum with placenta and all extraembryonic 
membranes. In situ hybridisation of this tissue revealed a specific distribution o f the 
E30 transcript. Figures 3.17A-C show sections of the uterus o f a pregnant mouse 
(16.5 dpc). E30 transcripts were detectable in the epithelium lining the uterus lumen. 
In contrast, the uterus stroma showed no signal. Furthermore we could detect the E30 
transcripts in the placenta, the yolk sac and the parietal endoderm (Fig. 3.17D-F). To 
obtain a more detailed pattern of expression, HE-counterstained sections were 
hybridised with the antisense probe. The accumulation o f silver grains (black dots) is 
clearly visible on top of the inner layer (parietal endoderm) of the deciduum wall (Fig. 
3.17H). Figure 3.171 shows E30 expression in yolk sac tissue. No signal was found in 
the amniotic tissue (note, that the tissue collapsed during preparation). The figure 
3.17K shows a higher magnification o f the yolk sac tissue, where it is forming a blood 
island. The yolk sac is composed o f the inner embryonal mesenchyme originating 
from the mesoderm and the outer visceral endoderm of endodermal origin. The 
expression of E30 is restricted to the visceral endoderm, as the accumulation o f grains 
indicated.
Figure 3.17: Expression of E30 in the uterus of a pregnant mouse and in extra embryonic tissue. (A-G) 
Transversal section through the uterus of mouse after 16.5 days of pregnancy. (A) Antisense 
hybridisation localises E30 transcripts in the uterus epithelium. (B) Control hybrl6sation. (C) HE 
staining. (D-E) section with extra embryonic tissue. (D) Antisense hybridisation showed signal in the 
placenta, yolk sac and parietal endoderm. (E) Sense hybridisation. (F) HE staining. (G-H) Antisense 
hybridisation of placenta and decidua wall. ^  Enlargement of a part of the decidua waU (boxed area in 
6). (I-J) Antisense and sense hybridisation showing signal in yolk sac, but not in amnion. (K)
Enlargement showing grains in the visceral endoderm of the yolk sac. ep, epithelium; iu, lumen; pi, 
placenta; ys, yolk sac; pe, parietal endoderm;dw, decidua wail; am, amnion; em, embryonal 
mesenchyme;ve, visceral endoderm; bi, blood island.
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Figure 3.18: Immune staining for E30 in mammary gland, enlarged mammary gland, testis, thymus, 
ovary and oviduct of the adult mouse. Immunostaining of the mammary gland. (A-B). Immunostaining 
of enlarged mammary gland. (C D) The epithelial cells in the enlarged area of mammary gland are 
stained. Immunostaining of testicular tissue. (E-F) Staining of the outer layer of seminiferous tubules. 
Magnification 200x. (G-H) Section of the thymus: meduUa and cortex parts are shown. Magnification 
lOOx (I-J) Secondary foUicle. Staining of the zona granulosa and of the oocyte itself is seen. 
Magnification 400x. (K-L) Oviduct The epithel Uning of the oviduct, containing ciliated ceUs, is stained. 
Magnification 40Qx. A H are hematoxylinstained, I-J are not counterstained, K-L are HE-stained. ge, 
germinal epithel, M, mucosa, C, cortex, 0, oocyte, ZG, zona granulosa, FA, foUicular antrum, ZP, zona 
peUucida.
Immunohistological staining with the anti-E30 antibody
The results obtained by immunohistochemical staining using the anti-E30 antibodies 
largely confirmed the data obtained by in situ hybridisation. The mammary, testis, 
liver, lung, ovary, oviduct, placenta, thymus and spleen were tested for expression of 
E30. There was staining in the epithelial layer o f the mammary gland (Fig. 3.18 A-B). 
Furthermore an enlarged mammary gland clearly stained positive (Fig. 3.18C-D). The 
E30 protein distribution in testis is coincident with the distribution of transcripts, 
where faint staining in the epithelium of the seminiferous tubules could be seen (Fig. 
3.18E-F) in either spermatogonias, primary spermatocytes, myoids or Sertoli cells. In 
thymus staining was observed in cortex and medulla (Fig. 3.18G-H), however 
intensity was weak in contrast to the strong signal obtained by in situ hybridisation. A 
similar but even fainter signal was obtained after staining of the section o f the spleen 
with the anti-E30 serum. Also the cells in and around the ovary stained i.e. the follicle 
cells in primary and secondary follicles and heavy staining of the oviduct could be 
observed. Also staining of the bile ducts o f the liver was observed (data not shown).
Immunohistological staining of the sections prepared from the uterus and placenta 
including the extraembryonic tissue also confirmed the in situ hybridisation results. 
Expression of the E30 gene was seen in the epithelial lining o f the lumen of the uterus 
(Fig. 3.19A-D), the visceral endoderm (Fig. 3.19E-G) of the yolk sac, the parietal 
endoderm of the deciduum wall (Fig. 3.19E, H-I) as well as in placenta (Fig. 3.19E).
Figure 3.19: Expression of E30 in the uterus of a pregnant mouse and in extra embryonic tissue. (A-D) 
Transversai section through the uterus of mouse after 16.5 days of pregnancy. (A) Immunostaining 
iocaiises E30 to the uterus epithelium. Approximately 40x magnification. (B) Same as A without primary 
antibodies (C-D) Section of A and B, respecüveiy magnified 400x. (E-I) Immunostaining of extraembryonic 
tissue. (E) Immunostaining showing staining of the placenta, yolk sac and parietal endoderm. 
Approximately 40x magnification. (F) Section showing staining in the visceral endoderm of the yolk sac. 
(G) Control staining without primary antibodies. Enlarged 400x. (H I) 400x enlargement of the parietal 
endoderm (H) stained with anü-E30 serum and (I) stained with secondary antibodies alone.
Abbreviations were as in Fig. 3.16. + and -  indicate use of anti-E30 antibody or not
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Figure 3.20: Transient transfection of 10T%-celIs with pRc/CMV-10 lead to E30 expression.
(A) The blunt-ended EcoRI cDNA sequence of E30 was cloned into pRc/CMV using Notl 
restricted, blunt-ended, dephosphorylated vector leading to a transcribed mRNA of the size of E30 
initiating with the transcriptional initiation site provided by pRc/CMV and ending with the bovine 
growth hormone (BGH) polyadenylation signal. Cloning and sequencing lead to the isolation of a 
vector containing the E30 in a sense direction (pRc/CMV-10) and in an anti-sense direction (pRc/CMV-11). 
IOTV2 cells were electrotransfected with the pRc/CMV-10 and pRc/CMV-11 vectors. After 24 hours the 
transfected cells were harvested (B and C) or stained (D). (B) Transcription of E30 was detected in transiently 
transfected IOTV2 cells. A Northern blot was prepared with app. 10 pg total RNA pr lane and transcription 
detected with labelled E30. The film was developed after over night exposure and after 3% days revealing 
expression of mainly a 1.8 kb product in the transfected cells and a 1.4 kb product in CSML-100 cells.
(C) Protein expression of E30 was detected in transiently transfected IGT'A cells. A Western blot using 
cell lysates of CSML-100, CSML-0 and IOTV2 cells, non-transfected or transfected with sense and anti­
sense expression vector, was performed. Equal amounts (app. 10.000 cells as judged from Ponceau 
staining of the filter after blotting) were separated on a 15% SDS-PAGE gel, blotted and stained with 
anti-E30 serum diluted 1:400. The size of the transfected E30 protein corresponds to CSML-100 expressed 
E30. (D) pRc/CMV-10 transfected IOTV2 cells were stained with anti-E30 serum. After 24 hours cells were 
acetone fixed and stained with anti-E30 serum diluted 1:100. A stained cell (black arrow) next to an unstained 
cell (transparent arrow) is shown. App. 10% of the cells were stained.
50
Transfection of CSML-0 cells to express E30 
Transient transfection
To test the suggestion that the E30 protein is involved in tumour progression, transient 
transfections of the non-tumourigenic 10X^2 and the non-metastatic CMSL-0 cell lines 
were performed (Fig. 3.20). IOTV2 cells were transfected transiently to test the 
capability of the constructed vectors (pRc/CMV-10 and pRc/CMV-11) (Fig. 3.20A). 
These constructs consist o f the pRc/CMV-vector and the EcoRl-ffagment of the 
cDNA-clone including the presumed translation initiating ATG-site at nucleotide 23, 
the stop site at nucleotide 1036 and the degenerated polyA-signals all described under 
Sequence information. Northern blot analysis showed strong expression of E30 
mRNA in sense transfected lOTK-cells, while the overexpression of antisense mRNA 
was less apparent (Fig. 3.20B). The size difference observed between the transfected 
E30 transcript o f 1.8 kb and CSML-100 E30 mRNA of 1.4 kb could be due to 
utilisation of the transcriptional start in the vector situated 120 bases upstream o f the 
insertion point and/or be due to usage of alternative signal for polyadenylation 
resulting in a prolonged 3’ end. There was no difference in size of the E30 protein in 
transfected cells and the expressed protein in CSML-100 cells, indicating that E30 is 
translated in full length (Fig. 3.20C). E30 protein expression was detected in CSML- 
100 and pRc/CMV-10 transfected lOT^ cells, while neither normal IOTV2 cells nor 
pRc/CMV-11 transfected 10T!4 cells expressed E30. The sense transfected lOTl/2 
cells overexpressing the E30 protein were stained by anti-E30 antibody shown in figure 
3.20D. Approximately 10% of the sense transfected cells stained positive. Staining was 
restricted and concentrated to the cytoplasm. In contrast, the untransfected cells (Fig. 
3.20D, unfilled arrow) and cells transfected with the antisense construct did not show 
staining (data not shown). There was no change in morphology between antisense and 
control transfected cells. Since 10% of the cells were transfected and the amount of 
protein expressed was about four times higher in sense transfected 1 OTYi cells than in 
CSML-100 cells, the average expression in transfected cells was increased 
approximately 40 times. An attempt to cytostain CSML-100 cells with anti-E30 serum 
failed probably because of the limited affinity of the immune serum.
Stable transfection
Clones expressing the E30 protein after transfecting CSML-0 cells with the pRc/CMV- 
10 construct were obtained (Fig. 3.21). Western blot analysis of protein extract jfrom
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clones transfected pRc/CMV-10 was used to identify clones expressing E30 after 3-5 
weeks in culture (Fig. 3.21 A). However, retesting the expression o f these cells 
approximately two weeks later showed loss of expression in eight cell lines. While 
nine clones were positive initially, three were positive two weeks later, with reduced 
expression in all cell lines. Subcloning of these cell lines led to the isolation o f one 
clone, 3E7-9-C010, a stably transfected E30 expressing CSML-0 cell line (Fig. 3.21B 
and C). The level o f E30 expression in this cell line was comparable to CSML-100 
expression. As mentioned above, this level of expression was too low for cytostaining 
with the available polyclonal antibodies. The expression of E30 protein did not 
change the morphology of the cells. The metastatic ability of 3E7-9-C010 cells were 
tested in syngeneic A/sn mice.
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Figure 3.21: Stable transfections of CSML-0 ceiis. (A) Western biot of pRc/CMV-lO (iane 1-19) or pRc/CMV-ll 
(lane 20-21) transfected CSML-0 ceiis showing expression of E30 in lane 2,8,9,13 and 17 (clone 1C6-C010, 
2D7-C010,2C11 COlO, 3E7-C010,3C3-C010) three weeks after transfection. E30 expression in CSML-100 ceiis 
was used as control. (B) Western blot of pRc/CMV-10 (lane 1-19) or pRc/CMV-11 (iane 20-21) transfected 
CSML-100 ceiis showing expression of E30 in ail lanes. (C) Western biot of clones subcioned from E30 
expressing 3E7-C010. Subcione number is indicated above the biot Only subcione 9 (3E7-9-C010) expresses 
E30 protein. App. 10.000 ceiis were loaded pr. iane in ail Western blots.
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Spontaneous metastasis assay
Eight mice were injected sub cutis (sc) with 10  ^cells (Table 3.2). The mice were 
injected with either 3E7-9-C010 or CSML-0. The cells injected (>95% viable) gave 
rise to primary tumours in 2/3 3E7-9-C010 injected mice and 4/5 CSML-0 injected 
mice. The tendency of even small tumours from CSML-0 cells to become necrotic 
was unchanged for the transfected cells and there was no other obvious changes in the 
morphology o f the primary tumours (Fig. 3.22 A-D). Also the sizes of the tumours 
were unchanged with an approximately one-week delay of initiation of growth in 
mice injected with transfected cells (Table 3.2). Examination of lungs and liver did 
not reveal any microscopic metastatic lesions.
Table 3.2:
Spontaneous metastatic assay using transfected CSML-0 cells.
M ouse
#
Cells injected Experiment
length®’
Initiation of tumour 
growth®’
Tumour 
size  (mm)
Remark
2061 3E7-9-C010 - - 0 No tumour
2062 3E7-9-C010 33 20 13
2063 3E7-9-C010 20 20 8
2076 CSML-0 0 No tumour
2077 CSML-0 20 20 11
2078 CSML-0 20 20 12
2079 CSML-0 20 13 14
2080 CSML-0 14 13 14
Days after sc injection of cells.
Experimental metastasis assay
In the experimental metastasis assay three mice were injected intravenously (iv, into 
the tail vein) with 10*’ o f 3E7-9-C010 or 8x10^ o f CSML-0 cells (Table 3.3). CSML-0 
cells very rarely and not at all in this experiment produces metastasis in an 
experimental or spontaneous metastasis assay. When injecting 3E7-9-C010 cells, two 
mice collapsed with métastasés in the lung and in the liver 64 and 69 days after 
injection, respectively. The first mouse was sacrificed after 33 days with no sign of 
metastatic growth. The volume o f metastatic lesions was massive with several large 
nodules and a few small (Fig. 3.23 and 3.24). The volume of the tumour mass in the 
lung o f the mice containing metastasis was comparable.
Figure 3.22: Hematoxylin-eosin stainings of prim ary tumours. Magnifications of 
approximately lOOx and 400x of tumours arising from CSML-0 and 3E7-9-C010 are shown.
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Figure 3.23: Hematoxylin-eosin stainings of metastasis in the liver of iv injected 3E7-9- 
COIO cells of mouse 2058. Sections of liver enhanced lOOx, 200x or 400x. An invasive 
area of the metastatic lesion can be seen.
Figure 3.24: Metastatic lesions from 3E7-9-C010. (A) Center of a large lesion arisen in 
mouse 2059 enhanced 200x. (B) Small nodule in the lung from animal 2059 enhanced 
400x
Table 3.3:
Experimental metastatic assay using transfected CSML-0 cells.
M ouse Cells injected 
#
Days after 
injection
Number of m etastasis
2058 3E7-9-C 010 69 In lung>4 and liver=1
2059 3E7-9-C 010 64 In lung>13 and liver=1
2060 3E7-9-C 010 33 0
2051 CSML-0 85 0
2052 CSML-0 85 0
2053 CSML-0 85 0
2054 CSML-0 85 0
2055 CSML-0 85 0
2056 CSML-0 85 0
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4. D iscussion
In order to identify transcriptional differences we compared mRNA expression of two 
metastatic cell lines CSML-100 and VMR-Li to non-metastatic CSML-0. Using DD 
56 fragments displaying differential expression were isolated. Ten o f these fragments 
were retested, cloned and shown to be differentially expressed in Northern blot 
analysis. Six o f them aligned to known genes (PACE4, Collagen XI a l ,  MMTV, 
Lamin C, Ly-6A/E and Cystatin C), three fragments were homologous to partially 
sequenced murine cDNA (homologues to clones 9-1, 18-4 and 30-8 were found in 
libraries from mammary gland, brain tissue and miscellaneous, respectively), while 
one fragment lacked homology to published sequences (clone 32-9). The expression 
pattern o f the fragments in 14 metastatic and non-metastatic cell lines pointed to a 
potential role o f the corresponding genes in tumour progression. The possible role of 
the two genes expressed in CSML-0, i.e. PACE4 and Collagen XI a l, in suppression 
o f metastasis was shown for the first time. The role of Lamin C, Cystatin C and Ly- 
6A/E in metastasis has been suggested previously validating DD for the identification 
o f differentially expressed genes involved in the metastatic process. Moreover, a new 
fragment (32-9), whose expression correlated with the metastatic potential o f tumour 
cells, was described as well as the expression o f three additional fragments shown to 
be EST-homologues. The coding region of one o f these fragments was cloned and 
named E30. This clone contained an open reading frame with 338 aa, theoretically 
resulting in a 39kDa protein. Preliminary data indicated an effect o f the expression of 
this gene in the metastatic process.
Differential display
The use o f DD to identify differences between closely related cell lines with different 
metastatic potential was successful, although drawbacks were encountered. Consistent 
with our results, false positive clones have often been reported (155; 156), making 
reproductive runs and Northern blot confirmation necessary prior to selection of 
differentially expressed bands. Additionally, the suitability o f the method depends on 
its ability to restrict the gene pool in a specific manner. The selection of 1/12 of the 
transcribed genes depends on the mRNA polyadenylation site being consistent i.e. o f 
the sequence preceding the poly-A end to correspond to: one gene -  one sequence. 
However, comparing sequences of the 3’-ends o f known genes from the database with
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the isolated cDNA, these sequences differed, indicating that the downstream primers 
selected 1/12 of the transcripts in the gene pool, but not 1/12 of the transcribed genes. 
The sequence o f the cDNA clone of E30 confirmed this, since it when compared to 
clone 30-8 contained three extra 3’ end nucleotides. As a consequence a few 
downstream primers and more upstream primers should be used to display a larger 
number of the transcribed genes.
It has been calculated, that a defined number of arbitrary upstream primer would 
display the entire population o f a given cell line (157). In this set-up, however, 
displaying approximately 700 bands representing a maximum of 700 genes of the 
estimated 10-15,000 expressed cellular genes, led to the isolation o f transcripts 
corresponding to MMTV and Lamin C gene, 5 and 4 times respectively. Expanding 
the DD, using additional primers, would increase this problem of isolating copies of 
identical genes.
Considering the above mentioned two points, displaying the entire pool of transcripts 
in the cell using DD might prove difficult. Compared to other methods like 
subtractive hybridisation and cDNA library screening, however, DD was a very 
efficient method for identifying differential gene transcription amongst closely related 
cell lines and it was possible to identify 17 reproducible differences, corresponding to 
30% true positives, among the isolated 56 fragments. Extrapolation of the identified 
10 differences, while displaying 700 gene fragments, leads to an estimated 200 
differences between CSML-0 and CSML-100 cell lines assuming 14.000 expressed 
genes in the cells. Since seven out of 17 fragments isolated corresponding to 41% 
were copies o f already identified differences, the 700 fragments represents less than 
700 gene fragments, this 200 is an underestimate. A guess closer to the actual number 
o f differences would be approximately double. This is in accordance with the recently 
applied SAGE technique, where 500 differences were found between normal prostate 
tissue and tumour tissue (158). None o f the differences found in that study, match 
sequences described in the present study. However, the differences in species, 
progression state and tissue could explain the discrepancy.
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Differential gene expression 
Genes expressed in CSML-0
The differential expression of the transcripts in the CSML cell line system suggested a 
possible involvement in tumour progression for the ten different genes identified. We 
compared the expression of the identified gene fragments with genes of known 
metastatic potential. A correlation was found between the expression of the genes 
coding for PACE4 and Collagen XI a  1 as compared to E-cadherin expression, 
supporting an involvement of the identified genes in the suppression o f tumour 
progression.
PACE4
PACE4 belongs to the KEX2/furin family of serine proteases. A function of the serine 
protease PACE4 in the suppression of tumour progression could be activation of 
proproteins in the cell. For example prohormones necessary for survival or 
proliferation, since PACE4 and other members of this family activate nerve growth 
factor (159), known to rescue serum-starved PC 12 cells from apoptosis (160; 161). 
Also proMTl-MMP was cleaved in vitro by fiirin, head of the family o f serine 
proteases to which PACE4 belong (162). It has been suggested that PACE4 is a 
tumour suppressor, due to a lack of expression in small cell lung cancer (163), and 
here we furthermore suggest an involvement in impeding tumour progression 
coinciding with this data.
Collagen XI a l
The expression of Collagen XI a  1 has not previously been connected to cancer 
progression, either. Alternative splicing seen in CSML-0 cells occurs during 
development in tissue destined to become bone (164), in chondrocytes (150) and has 
been demonstrated in the human rhabdomyosarcoma cell lines RD and A204 (165). The 
binding o f integrin 61 to molecules of the ECM has been shown to salvage cells from 
programmed cell death (166; 167), and Collagen XI contains a binding site for 
integrin a - 2  6-1 (168).
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Genes expressed in CSML-100
We correlated the expression of genes coding for Lamin C, Cystatin C and ly-6A/E to 
the same panel of mouse cell lines. The expression is widespread with an increased 
expression in cell lines that are metastatic in both assays.
Lamin C
The ubiquitously expressed transcript o f the nuclear envelope protein Lamin C was 
detected at lower levels in non-metastatic CSML-0, low metastatic M TITCI and 
RAC34E. The nuclear lamina in embryonic and lymphoid cells is composed 
exclusively o f Lamin B (169) indicating that differential lamin expression may play a 
role in proliferation or differentiation. In testis cancer, upregulation of Lamin C in 
four out o f four invasive non-seminoma tumours as compared with non-invasive 
carcinoma in situ points to a role in tumour malignancy (170), confirming a possible 
role of Lamin C in tumour progression.
Cystatin C
Transcripts of Cystatin C were widely expressed in the panel of mainly metastatic cell 
lines. Small amounts o f transcript as well as protein could be detected in CSML-0 
cells in vitro. Downregulation of Cystatin C protein expression seemed to occur in 
two RAC cell lines, RAC34E and RAC 1 OP. The difference in expression in the 
CSML cell system was confirmed when tumours originating from CSML-100 and 
CSML-0 cells were stained. Cystatin C was mainly expressed in the tumour 
originating from cells o f CSML-100. The non-focused nature of the staining could be 
due to the segregation o f the protein. The exogenous Cystatin C is a potent inhibitor 
o f a variety o f cysteine proteases, the main target being the lysosomal cathepsin B. 
Cathepsin B has been implicated in metastasis through reports stating that the 
upregulation of the protease correlates with metastasis (171; 172), cathepsin B can 
degrade basement membrane in vitro (173), it participates in tissue remodelling in 
vivo (174), it can activate u-PA (88) and is expressed on the invasive edge of 
malignant tissue (92). We found overall expression of Cystatin C in the tumour 
comprised o f metastasising CSML-100 cells and CSML-0 with higher expression in 
the CSML-100 tumour. The activity of Cathepsin B has been calibrated with the 
cysteine inhibitory activity in order to correlate the ratio of activity to malignancy (97; 
172; 175). However, the cysteine inhibitory activity was in the majority of the studies
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found to consist of Stefin A and B, two mainly intracellular cysteine protease 
inhibitors. It would be of interest to correlate the balance o f expression o f Cathepsin B 
and extracellular Cystatin C along with the localisation of the proteins in metastatic 
versus non-metastatic tumours.
Ly-6A/E
Ly-6A/E gene expression has been demonstrated in all but one cell line, which were 
metastatic in both assays (VMR-Ly, CSML-100, LL-Met, MT1TC3, but not VMR-Li), 
while it was undetectable in CSML-0, VMR-0 p9 and M TITCI (152). It is also found in 
the non-tumourigenic lOTK, the metastatic RAC5E and RAC34E and in low levels in 
the non-metastatic RAC 1 OP. Ly-6A/E is a lymphocyte surface protein of unknown 
function. However, transformation experiments showing a correlation between Ly-6A/E 
protein expression and malignancy (176) and the high level o f Ly-6A/E gene expression 
in metastatic cells, suggest involvement of the gene in tumour progression. A human Ly- 
6 homologue, CD59, has been shown to inhibit complementary destruction of the cell 
(177).
Unknown genes
We also identified three genes previously isolated as end sequenced tags (ESTs) and 
one gene not matching previously published sequences. Clone 9-1 appears to be o f 
interest, since expression of this gene was increased in the metastatic VMR-Li, VMR- 
Ly and CSML-100, while reduced in corresponding low or non-metastatic partners. 
Clone 18-4 initially proved promising present in CSML-0 only, however, loss of 
expression in this cell line discouraged further investigation. Clone 32-9 was initially 
found in CSML-100 and VMR-Li, but not in CSML-0. Isolating cDNA-clones 
hybridised with this fragment resulted in the eight clones identical to galectin-1 (data 
not shown). These clones, however, did not contain any homology to clone 32-9. 
Clone 30-8 was expressed in the majority of the cell lines metastatic in the 
experimental and spontaneous assay indicating a role for the corresponding gene in 
metastasis:
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E30:
Isolation of cDNA clone and characterisation
Clone 30-8 was used for screening a cDNA-library. A 1-phage cDNA clone of E30 
(clone E30-8-2) was isolated. The sequence contained 1154 bp, while Northern blot 
analysis of E30 revealed a mRNA fragment approximately 1.4 kb in size. This 
discrepancy could be explained by lack of polyA-end in the cDNA-clone and missing 
nucleotides 5’. Estimating the size of the poly-A end to around 200 bp this allows for 
approximately 50 uncloned 5’ nucleotides. Also the sequence of the potential 
translational initiation site conforms closely to the rules set out by Kozak et al. 1991 
further supporting the cloning of the complete coding sequence. The polyadenylation 
signal was not the usual AATAA, but three sites mutated in one position situated less 
than 23 nucleotides from the 3’ end (TATAA, GATAA, AATTA) might impose for a 
polyadenylation signal. Sequence analysis revealed an open reading frame spanning 
1014 nucleotides resulting in a potential 338 aa protein with a predicted size o f 39kDa. 
Comparison of native CSML-100 expressing endogenous E30 with CSML-0 cell line 
transfected with E30 expression vector, revealed no difference in gel mobility. Western 
blotting experiments showed that the polyclonal anti-E30 serum showed reactivity 
against a protein of the expected size (Fig. 3.13C). Transfection experiments confirmed 
the reactivity of anti-E30 serum displaying the occurrence of an approximately 39kDa 
protein. It was therefore concluded that cDNA clone E30-8-2 contained the complete 
coding sequence of the E30 gene.
The specificity of the polyclonal antibody was also addressed. Adding recombinant 
fusion protein to the assay blocked the reactivity against the supposed E30 protein. Also 
the expression pattern of E30 protein correlated with findings o f mRNA expression. 
The transfection experiments demonstrated the appearance of a protein of the correct 
size in sense transfected cells. The results obtained by in situ hybridisations supported 
the immunohistological data. For example placenta, yolk sac, parietal endoderm, and the 
epithelial lining of the lumen in uterus were demonstrated to express E30 in both assays. 
However, the antibody did not stain native CSML-100 cells or tumours. This low 
sensitivity in immunocytochemical and immunohistological stainings impeded thorough 
investigation of the expression of E30 in tissue and transfected cells in vitro and in vivo.
62
In conclusion the antibody reacted specifically with E30 and was suitable for staining 
protein in Western blot analysis and not too demanding immunohistological stainings.
The E30 family of proteins
The protein sequence revealed an unknown protein. Extensive searches in various 
databases revealed no protein homologies. Also analysis of the sequence of the protein 
with respect to protein motifs, except for potential phosphorylation sites and N- 
glycosylation sites, failed to disclose functional data. However, EST fi*agments from 
mus musculus, homo sapiens and caenorhabditis elegans were found showing homology 
to the E30 sequence (Fig. 3.11 and Fig. 3.12). As mentioned previously, the information 
obtained from EST data was limited to a short sequence and the origin of the cDNA 
from which this short sequence was obtained. Hence, no functional data could be 
extracted from these data. Since all murine tags (23 ESTs in all) were 96% to 100% 
identical with E30, familywise E30 was the only expressed member found in mice. In C. 
elegans only a single EST-fi-agment homologous to E30 was described pointing to a 
protein, whose homologues could be preserved in various distantly related species. In 
human, four EST-ffagments were found, overlapping each other, two by two. While the 
Jurkat and human intestine sequences C-terminally were 98% identical, the N-terminal 
human foetal heart and human liver were only 47% identical on DNA level and 59% 
identical on protein level. Though, EST-firagments are known to contain many 
sequencing errors, this difference indicates the existence of two human genes belonging 
to the E30 family of proteins.
Localisation of E30 in the cell
CSML-100 cells were fractionated into a cytoplasmic, cytosolic and nuclear fraction. By 
Western blot analysis E30 was detected mainly in the cytoplasmic fraction with small 
amounts detected in the cytoskeletal fi-action. The cytoplasmic expression was also 
found in the cytostaining of the transient transfection. Whether a small amount was 
exported or transported to the nucleus would probably not be revealed using the 1816 
anti-E30 serum in this assay. However, the cytoplasmic localisation was in concordance 
with protein sequence analysis, since neither a signal sequence nor a transmembrane 
region was discovered. E30 is therefore currently believed to be a cytoplasmic protein. 
The protein sequence of E30 did not reveal a possible function. The finding of C. 
elegans and human homologues indicated a function o f E30 family proteins in distantly
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related species. Five tryptophan residues N-terminal, at least one of them conserved, 
could indicate that this region of E30 is important for ligand binding.
E30 expression
Western blot analysis showed tissue expression in liver, thymus, spleen, lung, heart, 
brain, kidney and testis. Epithelial cells and lymphocytes were stained to test the 
expression in more detail. E30 was expressed in the following epithelial tissue: the 
epithelial lining of the uterus of pregnant mouse, the epithelial cells in the mammary 
gland and an enlargement therein, the mucosa of the stomach, the columnar epithelial 
lining of the oviduct, the epithelial part of the yolk sac, the epithelial layer of the 
deciduum wall, the columnar epithelium and the lamina propria of the trachea and the 
bile ducts o f the liver. There are also indications for E30 expression in lymphocytes. 
First, E30 transcripts and proteins were found in spleen and thymus. Second, ESTs 
were isolated in lymph nodes and in T-cells.
Expression during embryogenesis indicates that E30 plays and important role in lung, 
liver and skeletal muscle development. Liver expression at 12.5dpc and expression in 
skeletal muscle and lung at 14.5dpc and 16.5dpc were detected as well as several 
ESTs from the blastocyst to 19.5dpc. The last general theme in the expression o f E30 
was expression in both the female and male reproductive system. In testis the outer 
layer o f the germinal epithelia as well as the follicular cells of the primary and 
secondary follicle expressed E30.
E30 therefore was found to be especially abundant in highly proliferative epithelial 
cells in organs such as uterus and stomach and in embryonic and extraembryonic 
tissue. Also expression in mature lymphocytes (ESTs) and lymphatic tissue was 
observed.
Involvement in metastasis
Expression studies of E30 indicated an involvement in tumour progression in the CSML 
and Miller cells. Although E30 was found in libraries of the mammary gland, expression 
of this gene was downregulated in most non-metastatic adenocarcinoma derived cell 
lines by impeding transcription.
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More importantly, the preliminary in vivo data of the transfected CSML-0 suggested an 
involvement of this gene in metastasis formation. While tumour formation was 
unchanged as compared to untransfected CSML-0 cells, sense transfected CSML-0 cells 
produced metastasis in the experimental assay. Metastasis was observed in two of the 
mice injected with 3E7-9-C010, with few but large métastasés in the lung and liver. The 
reason for the lack of metastasis formation in the first mouse could be due to the short 
time allowed before it was sacrificed. Several experiments performed in the laboratory 
did not show a metastatic capability of CSML-0 cells. Hence, though no effect on 
formation of the primary tumour was observed, the ability to form metastasis was 
enhanced in sense transfected CSML-0 cells and the ability to spread to the liver was 
unique for these cells. Since cells when injected through the tail pass the lung before the 
liver, this indicated a potential of E30 to regulate metastasis formation in different 
organs.
General considerations when studying metastasis
The process of tumour cell spreading is complex. Its multi-step nature in the not fully 
understood mammalian organism, most probably offers many possible pathways 
when primary tumours spread. One of the in vivo assays most frequently used for 
testing metastasis is an end point assay used here detecting metastasis in various 
organs after injection of test cells either sc or iv. This assay is sensitive to changes 
leading to different results with the same cells in different laboratories (e.g. M TITCI 
and 4T07 cells were described as non-metastatic, but were found to be metastatic 
when tested in this laboratory). The rate-limiting step (intravasation, circulation, 
extravasation, proliferation) hindering metastasis of the non-metastatic cell is often 
unknown. It was shown that TIMP-1 transfected B-16 metastatic melanoma cells were 
rendered non-metastatic (80). However, intravital video microscopy demonstrated that 
the cells were capable of invasion, but unable to proliferate in the tissue. The cell line 
chosen to test a specific theory is of utmost importance, however, little is known 
about the rate limiting step o f many of the non-metastatic cell lines and the metastatic 
pathways of the metastatic cell lines used in the laboratory today.
Since the number of differences between closely related cell lines with different 
metastatic potential could easily reach 500, it would be rather unlikely, via 
transfection of a single gene into the non-metastatic cell, to render it metastatic. If
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possible this could either indicate: 1) extreme luck, 2) the existence of many available 
pathways for metastasis lacking just one protein, 3) the existence o f one or more 
master genes switching on the metastatic process making the transfected gene one of 
these or an upstream target o f this or 4) a balance of metastasis versus non-metastasis 
for the supposedly non-metastatic cell line, rendering it metastatic when given just a 
small extra advantage. If the last theory is confirmed transfection o f the non­
metastatic cell will have a good chance of success if the gene has metastatic potential 
and the non-metastatic cell is almost capable o f metastasis. All in all, the selection of 
the right cell line, complemented for metastasis when transfected with E30, is crucial.
In this study we isolated fragments differentially expressed in the CSML cell line 
system and compared this expression with the M Tl, RAC and VMR cell line systems. 
Several proteins, like E-cadherin, thought to induce or impede tumour progression 
have been identified (178). A 100% correlation of E-cadherin (as for the identified 
transcripts) can not be seen. Several additional experiments should be considered to 
further illuminate the potential role of the identified genes in tumour progression. 
Protein expression, localisation, proteases balanced by their inhibitors produced either 
in the stroma or by the tumour itself, should be addressed. The plasmin activator 
system consisting of several activators and inhibitors balancing each other in normal 
tissue (57) and the localisation of the protease or its inhibitor at the invasive edge or 
inside the tumour (58; 179) have been demonstrated for uPA, making its contribution 
to the metastatic process likely. To convincingly show the potential of the identified 
genes in the metastatic process, transfection experiments should be performed. Hence, 
thorough investigations are needed in order to include or exclude proteins as 
participants in the metastatic process.
5. C o n c lu s io n
In summary, the results demonstrate DD as an effective method for screening several 
cell types for differentially expressed mRNA. I identified genes not previously 
described in connection with metastasis and point to possible novel pathways of the 
metastatic process. Additional experiments should be performed to understand the 
contribution of these genes to the metastasis and the usefulness of the identified genes 
as diagnostic markers. Complete coding sequence of one of the identified genes.
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named E30, was cloned. Transfection experiments o f E30 demonstrated an 
involvement of this previously undescribed gene in metastasis.
67
6. R eferen ce L ist
1. Fidler, I.J. Biology of cancer metastasis. Cancer Mag., Oct. : 23-27, 1990.
2. Ozawa, M., Engel, J., and Kemler, R. Single amino acid substitutions in one Ca2-i- binding site of 
uvomorulin abolish the adhesive function. Cell, 63: 1033-1038, 1990.
3. Overduin, M., Harvey, T.S., Bagby, S., Tong, K.I., Yau, P., Takeichi, M., and Ikura, M. Solution 
structure o f the epithelial cadherin domain responsible for selective cell adhesion. Science, 267: 
386-389, 1995.
4. Ozawa, M., Baribault, H., and Kemler, R. The cytoplasmic domain of the cell adhesion molecule 
uvomorulin associates with three independent proteins stmcturally related in different species. 
EMBO J., 5; 1711-1717, 1989.
5. Stappert, J. and Kemler, R. A short core region of E-cadherin is essential for catenin binding and 
is highly phosphorylated. Cell Adhes.Commun., 2: 319-327, 1994.
6. Butz, S. and Kemler, R. Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell 
adhesion. FEBS Lett., 255: 195-200, 1994.
7. Hinck, L., Nathke, I.S., Papkoff, J., and Nelson, W.J. Dynamics of cadherin/catenin complex 
formation: novel protein interactions and pathways of complex assembly. J.Cell Biol., 125: 1327- 
1340, 1994.
8. Reynolds, A.B., Daniel, J., McCrea, P.D., Wheelock, M.J., Wu, J., and Zhang, Z. Identification of 
a new catenin: the tyrosine kinase substrate pl20cas associates with E-cadherin complexes. 
Mol.Cell Biol., 14: 8333-8342, 1994.
9. Nagafuchi, A. and Takeichi, M. Transmembrane control o f cadherin-mediated cell adhesion: a 94 
kDa protein functionally associated with a specific region of the cytoplasmic domain o f E- 
cadherin. Cell Regul., 1: 37-44, 1989.
10. Aberle, H., Butz, S., Stappert, J., Weissig, H., Kemler, R., and Hoschuetzky, H. Assembly o f the 
cadherin-catenin complex in vitro with recombinant proteins. J.Cell Sci., 107: 3655-3663, 1994.
11. Wollner, D.A., Krzeminski, K.A., and Nelson, W.J. Remodeling the cell surface distribution of  
membrane proteins during the development of epithelial cell polarity. J.Cell Biol., 116: 889-899, 
1992.
12. Bracke, M.E., Van, R.F., and Mareel, M.M. The E-cadherin/catenin complex in invasion and 
metastasis. Curr.Top.Microbiol.Immunol., 275: 123-161, 1996.
13. Frixen, U.H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and 
Birchmeier, W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human 
carcinoma cells. J.Cell Biol., 113: 173-185, 1991.
14. Vleminckx, K., Vakaet, L., Mareel, M., Fiers, W., and van, R.F. Genetic manipulation of E- 
cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66: 107- 
119, 1991.
15. Behrens, J., Birchmeier, W., Goodman, S.L., and Imhof, B.A. Dissociation of MDCK epithelial 
cells by the monoclonal antibody anti-arc-1 : mechanistic aspects and identification of the antigen 
as a component related to uvomomlin. J.Cell Biol., 101: 1307-1315, 1985.
16. Ozawa, M. and Kemler, R. Correct proteolytic cleavage is required for the cell adhesive function 
of uvomomlin. J.Cell Biol., I l l :  1645-1650, 1990.
68
17. Kadowaki, T., Shiozaki, H., Inoue, M., Tamura, S., Oka, H., Doki, Y., lihara, K., Matsui, S., 
Iwazawa, T., Nagafuchi, A., and et, a. E-cadherin and alpha-catenin expression in human 
esophageal cancer. Cancer Res., 54: 291-296, 1994.
18. Oyama, T., Kanai, Y., Ochiai, A., Akimoto, S., Oda, T., Yanagihara, K., Nagafuchi, A., Tsukita, 
S., Shibamoto, S., Ito, F., and et, a. A truncated beta-catenin disrupts the interaction between E- 
cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell 
lines. Cancer Res., 54: 6282-6287, 1994.
19. Kawanishi, J., Kato, J., Sasaki, K., Fujii, S., Watanabe, N., and Niitsu, Y. Loss of E-cadherin- 
dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, 
HSC-39. Mol.Cell Biol., 15: 1175-1181, 1995.
20. Miller, J R. and Moon, R.T. Signal transduction through beta-catenin and specification of cell fate 
during embryogenesis. Genes Dev., 10: 2527-2539, 1996.
21. van, L.F. and Nusse, R. Oncogene activation and oncogene cooperation in MMTV-induced 
mouse mammary cancer. Semin.Cancer Biol., 6: 127-133, 1995.
22. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. Regulation o f intracellular 
beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. 
Proc.Natl.Acad.Sci.U.S.A., 92: 3046-3050, 1995.
23. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. Binding of GSK3P to 
the APC-P-catenin complex and regulation of complex assembly. Science, 272: 1023-1026, 1996.
24. Korinek, V., Barker, N., Morin, P.J., van, W.D., de, W.R., Kinzler, K.W., Vogelstein, B., and 
Clevers, H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon 
carcinoma. Science, 275: 1784-1787, 1997.
25. Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K.W. 
Activation o f beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. 
Science, 275: 1787-1790, 1997.
26. Rubinfeld, B., Robbins, P., El, G.M., Albert, 1., Porfiri, E., and Polakis, P. Stabilization o f beta- 
catenin by genetic defects in melanoma cell lines. Science, 275: 1790-1792, 1997.
27. Tamkun, J.W., DeSimone, D.W., Fonda, D., Patel, R.S., Buck, C., Horwitz, A.F., and Hynes,
R.O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between 
flbronectin and actin. Cell, 46: 271-282, 1986.
28. Ruoslahti, E. and Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. 
Science, 238: 491-497, 1987.
29. Hynes, R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11-25, 
1992.
30. Suzuki, S. and Naitoh, Y. Amino acid sequence of a novel integrin beta 4 subunit and primary 
expression o f the mRNA in epithelial cells. EMBO J., 9: 757-763, 1990.
31. Dedhar, S. Integrin mediated signal transduction in oncogenesis: an overview. Cancer Metastasis 
Rev., 14: 165-172, 1995.
32. Gille, J. and Swerlick, R.A. Integrins: role in cell adhesion and communication. 
Ann.N.Y.Acad.Sci., 797: 1996.
33. Hemler, M.E. VLA proteins in the integrin family: structures, functions, and their role on 
leukocytes. Armu.Rev.Immunol., 8:365-400: 365-400, 1990.
69
34. Rosen, G.D., Sanes, J.R., LaChance, R., Cunningham, J.M., Roman, J., and Dean, D C. Roles for 
the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell, 69: 1107-1119, 1992.
35. Cepek, K.L., Shaw, S.K., Parker, C.M., Russell, G.J., Morrow, J.S., Rimm, D.L., and Brenner, 
M.B. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha 
E beta 7 integrin. Nature, 372: 190-193, 1994.
36. Chen, Q., Kinch, M.S., Lin, T.H., Burridge, K., and Juliano, R.L. Integrin-mediated cell adhesion 
activates mitogen-activated protein kinases. J.Biol.Chem., 269: 26602-26605, 1994.
37. Schlaepfer, D.D., Hanks, S.K., Hunter, T., and van-der, G.P. Integrin-mediated signal transduc­
tion linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372: 786-791, 
1994.
38. Kapron, B.C., Fitz, G.L., Jeevaratnam, P., Wilkins, J., and Dedhar, S. Stimulation of tyrosine 
phosphorylation and accumulation of GTP-bound p21ras upon antibody-mediated alpha 2 beta 1 
integrin activation in T-lymphoblastic cells. J.Biol.Chem., 268: 20701-20704, 1993.
39. Vuori, K. and Ruoslahti, E. Association o f insulin receptor substrate-1 with integrins. Science, 
266: 1576-1578, 1994.
40. Montgomery, A.M., Reisfeld, R.A., and Cheresh, D A. Integrin alpha v beta 3 rescues melanoma 
cells from apoptosis in three-dimensional dermal collagen. Proc.Natl.Acad.Sci.U.S.A., 91: 8856- 
8860, 1994.
41. Zhang, Z., Vuori, K., Reed, J.C., and Ruoslahti, E. The alpha 5 beta 1 integrin supports survival 
of cells on flbronectin and up-regulates Bcl-2 expression. Proc.Natl.Acad.Sci.U.S.A., 92: 6161- 
6165, 1995.
42. Brooks, P.C., Clark, R.A., and Cheresh, D.A. Requirement o f vascular integrin alpha v beta 3 for 
angiogenesis. Science, 264: 569-571, 1994.
43. Filardo, E.J., Brooks, P.C., Deming, S.L., Damsky, C., and Cheresh, D.A. Requirement o f the 
NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro 
and in vivo. J.Cell Biol., 130: 441-450, 1995.
44. Nip, J., Shibata, H., Loskutoff, D.J., Cheresh, D.A., and Brodt, P. Human melanoma cells derived 
from lymphatic métastasés use integrin alpha v beta 3 to adhere to lymph node vitronectin. 
J.Clin.Invest., 90: 1406-1413, 1992.
45. Gehlsen, K.R., Davis, G.E., and Sriramarao, P. Integrin expression in human melanoma cells with 
differing invasive and metastatic properties. Clin.Exp.Metastasis, 10: 111-120, 1992.
46. Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., and Buck,
C.A. Integrin distribution in malignant melanoma: association o f the beta 3 subunit with tumor 
progression. Cancer Res., 50: 6757-6764, 1990.
47. Brooks, P.C., Stromblad, S., Sanders, L.C., von, S.T., Aimes, R.T., Stetler, S.W., Quigley, J.P., 
and Cheresh, D.A. Localization o f matrix metalloproteinase MMP-2 to the surface of invasive 
cells by interaction with integrin alpha v beta 3. Cell, 85: 683-693, 1996.
48. Chan, B.M., Matsuura, N., Takada, Y., Zetter, B.R., and Hemler, M.E. In vitro and in vivo 
consequences of VLA-2 expression on rhabdomyosarcoma cells. Science, 257: 1600-1602, 1991.
49. Riikonen, T., Westermarck, J., Koivisto, L., Broberg, A., Kahari, V.M., and Heino, J. Integrin 
alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(1) gene 
expression. J.Biol.Chem., 279: 13548-13552, 1995.
70
50. Stroeken, P.J., van Rijthoven, E.A., van der Valk, M.A., and Roos, E. Targeted disruption o f the 
betal integrin gene in a lymphoma cell line greatly reduces metastatic capacity. Cancer Res., 58: 
1569-1577, 1998.
51. Naot, D., Sionov, R.V., and Ish, S.D. CD44: stmcture, function, and association with the 
malignant process. Adv.Cancer Res., 77:241-311, 1997.
52. Bourguignon, L.Y., Lokeshwar, V.B., Chen, X., and Kerrick, W.G. Hyaluronic acid-induced 
lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. 
J.Immunol., 757: 6634-6644, 1993.
53. Lacy, B.E. and Underhill, C.B. The hyaluronate receptor is associated with actin filaments. J.Cell 
Biol., 105: 1395-1404, 1987.
54. Birch, M., Mitchell, S., and Hart, I.R. Isolation and characterization of human melanoma cell 
variants expressing high and low levels o f CD44. Cancer Res., 57: 6660-6667, 1991.
55. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, 
A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to 
rat carcinoma cells. Cell, 65: 13-24, 1991.
56. Rudy, W., Hofmann, M., Schwartz, A.R., Zoller, M., Heider, K.H., Ponta, H., and Herrlich, P.
The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from 
different splice variants: each one individually suffices to confer metastatic behavior. Cancer 
Res., 53: 1262-1268, 1993.
57. Andreasen, P.A., Kjoller, L., Christensen, L., and Duffy, M.J. The urokinase-type plasminogen 
activator system in cancer metastasis: a review. Int.J.Cancer, 72: 1-22, 1997.
58. Pyke, C., Kristensen, P., Ralfkiaer, E., Grondahl, H.J., Eriksen, J., Blasi, F., and Dano, K. 
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells 
at invasive foci in human colon adenocarcinomas. Am.J.Pathol., 138: 1059-1067, 1991.
59. Morita, Y ., Hayashi, Y ., Wang, Y ., Kanamaru, T., Suzuki, S., Kawasaki, K., Ohta, K.,
Yamamoto, M., Saitoh, Y., Itoh, H., and Doe, W.F. Expression of urokinase-type plasminogen 
activator receptor in hepatocellular carcinoma. Hepatology, 25: 856-861, 1997.
60. Xing, R.H. and Rabbani, S. A. Overexpression of urokinase receptor in breast cancer cells results 
in increased tumor invasion, growth and metastasis. Int.J.Cancer, 67: 423-429, 1996.
61. Kook, Y.H., Adamski, J., Zelent, A., and Ossowski, L. The effect o f antisense inhibition o f uroki­
nase receptor in human squamous cell carcinoma on malignancy. EMBO J., 13: 3983-3991, 1994.
62. Yu, H R. and Schultz, R.M. Relationship between secreted urokinase plasminogen activator 
activity and metastatic potential in murine B16 cells transfected with human urokinase sense and 
antisense genes. Cancer Res., 50: 7623-7633, 1990.
63. Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L.G., Brodt, P., Goltzman, D., and Rabbani, 
S.A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in 
vivo. Cancer Res., 54: 2372-2377, 1994.
64. Chambers, A.F. and Matrisian, L.M. Changing views of the role of matrix metalloproteinases in 
metastasis. J.Natl.Cancer Inst., 59: 1260-1270, 1997.
65. Liotta, L.A., Thorgeirsson, U.P., and Garbisa, S. Role o f collagenases in tumor cell invasion. 
Cancer Metastasis Rev., 7: 277-288, 1982.
66. Borden, P. and Heller, R.A. Transcriptional control o f matrix metalloproteinases and the tissue 
inhibitors o f matrix metalloproteinases. Crit.Rev.Eukaryot.Gene Expr., 7: 159-178, 1997.
71
67. MacDougall, J.R. and Matrisian, L.M. Contributions o f tumor and stromal matrix 
metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 
351-362, 1995.
68. Yamagata, S., Ito, Y., Tanaka, R., and Shimizu, S. Gelatinases of metastatic cell lines o f murine 
colonic carcinoma as detected by substrate-gel electrophoresis. Biochem.Biophys.Res.Commun., 
151: 158-162, 1988.
69. Yamagata, S., Tanaka, R., Ito, Y., and Shimizu, S. Gelatinases of murine metastatic tumor cells. 
Biochem.Biophys.Res.Commun., 158: 228-234, 1989.
70. van der Stappen, J.W., Hendriks, T., and Wobbes, T. Correlation between collagenolytic activity 
and grade o f histological differentiation in colorectal tumors. Int.J.Cancer, 45: 1071-1078, 1990.
71. Wirl, G. and Frick, J. Collagenase—a marker enzyme in human bladder cancer? Urol.Res., 7: 
103-108, 1979.
72. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix 
metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370: 61-65, 1994.
73. Kusukawa, J., Sasaguri, Y., Shima, I., Kameyama, T., and Morimatsu, M. Expression o f matrix 
metalloproteinase-2 related to lymph node metastasis o f oral squamous cell carcinoma. A 
clinicopathologic study. Am.J.Clin.Pathol., 99: 18-23, 1993.
74. Bernhard, E.J., Gruber, S.B., and Muschel, R.J. Direct evidence linking expression of matrix 
metalloproteinase 9 (92- kDa gelatinase/collagenase) to the metastatic phenotype in transformed 
rat embryo cells. Proc.Natl.Acad.Sci.U.S.A., 91: 4293-4297, 1994.
75. Bernhard, E.J., Muschel, R.J., and Hughes, E.N. Mr 92,000 gelatinase release correlates with the 
metastatic phenotype in transformed rat embryo cells. Cancer Res., 50: 3872-3877, 1990.
76. Kawamata, H., Kameyama, S., Kawai, K., Tanaka, Y., Nan, L., Barch, D.H., Stetler-Stevenson, 
W.G., and Oyasu, R. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma 
cell line by the expression of human gelatinase A. Int.J.Cancer, 63: 568-575, 1995.
77. Bramhall, S.R. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From 
molecular science to a clinical application. Int.J.Pancreatol., 21: 1-12, 1997.
78. Khokha, R., Waterhouse, P., Yagel, S., Lala, P.K., Overall, C.M., Norton, G., and Denhardt, D.T. 
Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 
cells. Science, 243: 947-950, 1989.
79. Tsuchiya, Y., Sato, H., Endo, Y., Okada, Y., Mai, M., Sasaki, T., and Seiki, M. Tissue inhibitor of 
metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell 
line, KKLS, in the chick embryo. Cancer Res., 53: 1397-1402, 1993.
80. Khokha, R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma 
cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. 
J.Natl.Cancer Inst., 86: 299-304, 1994.
81. Schultz, R.M., Silberman, S., Persky, B., Bajkowski, A.S., and Carmichael, D.F. Inhibition by 
human recombinant tissue inhibitor o f metalloproteinases of human amnion invasion and lung 
colonization by murine B16-F10 melanoma cells. Cancer Res., 48: 5539-5545, 1988.
82. Soloway, P.D., Alexander, C.M., Werb, Z., and Jaenisch, R. Targeted mutagenesis o f Timp-1 
reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of 
the host. Oncogene, 13: 2307-2314, 1996.
72
83. Gasson, J.C., Golde, D.W., Kaufman, S.E., Westbrook, C.A., Hewick, R.M., Kaufman, R.J., 
Wong, G.G., Temple, P.A., Leary, A.C., Brown, E.L. et al. Molecular characterization and ex­
pression o f the gene encoding human erythroid-potentiating activity. Nature, 3I5\ 768-771, 1985.
84. Sloane, B E. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin.Cancer 
Biol., 7: 137-152, 1990.
85. Lah, T.T., Kokalj, K.M., Stmkelj, B., Pungercar, J., Barlic, M.D., Drobnic, K.M., Kastelic, L., 
Babnik, J., Golouh, R., and Turk, V. Stefins and lysosomal cathepsins B, L and D in human breast 
carcinoma. Int.J.Cancer, 50\ 36-44, 1992.
86. Tooze, J., Hollinshead, M., Hensel, G., Kem, H.F., and Hoflack, B. Regulated secretion of mature 
cathepsin B from rat exocrine pancreatic cells. Eur.J.Cell Biol., 56: 187-200, 1991.
87. Buck, M.R., Karustis, D.G., Day, N.A., Hoim, K.V., and Sloane, B.F. Degradation of 
extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem.J., 
282: 273-278, 1992.
88. Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Gunzler, 
W.A., Janicke, F., and Graeff, H. Cathepsin B efficiently activates the soluble and the tumor cell 
receptor-bound form o f the proenzyme urokinase-type plasminogen activator (Pro-uPA). 
J.Biol.Chem., 266: 5147-5152, 1991.
89. Rozhin, J., Robinson, D., Stevens, M.A., Lah, T.T., Honn, K.V., Ryan, R.E., and Sloane, B.F. 
Properties o f a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic 
B16 melanoma variants. Cancer Res., 47: 6620-6628, 1987.
90. Sloane, B.F., Rozhin, J., Johnson, K., Taylor, FI., Crissman, J.D., and Honn, K.V. Cathepsin B: 
association with plasma membrane in metastatic tumors. Proc.Natl.Acad.Sci.U.S.A., 83: 2483- 
2487, 1986.
91. Spiess, E., Bruning, A., Gack, S., Ulbricht, B., Spring, H., Trefz, G., and Ebert, W. Cathepsin B 
activity in human lung tumor cell lines: ultrastmctural localization, pH sensitivity, and inhibitor 
status at the cellular level. J.Histochem.Cytochem., 42: 917-929, 1994.
92. Sinha, A.A., Gleason, D.F., Deleon, O F., Wilson, M.J., and Sloane, B.F. Localization of a 
biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and 
invasive edges by in situ hybridization. Anat.Rec., 235: 233-240, 1993.
93. Sloane, B.F., Dunn, J.R., and Horui, K.V. Lysosomal cathepsin B: correlation with metastatic 
potential. Science, 272: 1151-1153, 1981.
94. Sloane, B.F., Honn, K.V., Sadler, J.G., Turner, W.A., Kimpson, J.J., and Taylor, J.D. Cathepsin B 
activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res., 42: 980- 
986, 1982.
95. Corticchiato, O., Cajot, J.F., Abrahamson, M., Chan, S.J., Keppler, D., and Sordat, B. Cystatin C 
and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. 
Int.J.Cancer, 52: 645-652, 1992.
96. Hirano, T., Manabe, T., and Takeuchi, S. Serum cathepsin B levels and urinary excretion of 
cathepsin B in the cancer patients with remote metastasis. Cancer Lett., 70: 41-44, 1993.
97. Rozhin, J., Gomez, A.P., Ziegler, G.H., Nelson, K.K., Chang, Y.S., Fong, D., Onoda, J.M., Honn, 
K.V., and Sloane, B.F. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell 
subpopulations isolated from murine tumors. Cancer Res., 50: 6278-6284, 1990.
98. Sexton, P.S. and Cox, J.L. Inhibition of motility and invasion of B16 melanoma by the 
overexpression of cystatin C. Melanoma.Res., 7: 97-101, 1997.
73
99. Koop, S., MacDonald, I.C., Luzzi, K., Schmidt, E.E., Morris, V.L., Grattan, M., Khokha, R., 
Chambers, A.F., and Groom, A.C. Fate of melanoma cells entering the microcirculation: over 
80% survive and extravasate. Cancer Res., 55: 2520-2523, 1995.
100. Koop, S., Khokha, R., Schmidt, E.E., MacDonald, I.C., Morris, V.L., Chambers, A.F., and 
Groom, A.C. Overexpression o f metalloproteinase inhibitor in B16F10 cells does not affect 
extravasation but reduces tumor growth. Cancer Res., 54: 4791-4797, 1994.
101. Nakamura, T. Structure and function of hepatocyte growth factor. Prog.Growth Factor Res 3- 
67-85, 1991.
102. Stoker, M., Gherardi, E., Perryman, M., and Gray, J. Scatter factor is a fibroblast-derived 
modulator o f epithelial cell mobility. Nature, 327: 239-242, 1987.
103. Nakamura, T., Teramoto, H., and Ichihara, A. Purification and characterization of a growth factor 
from rat platelets for mature parenchymal hepatocytes in primary cultures. 
Proc.Natl.Acad.Sci.U.S.A., 83: 6489-6493, 1986.
104. Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., Daikuhara, Y., 
Tsubouchi, H., Blasi, F., and Comoglio, P.M. Extracellular proteolytic cleavage by urokinase is 
required for activation of hepatocyte growth factor/scatter factor. EMBO J., 77: 4825-4833, 1992.
105. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y., and Kitamura, N. 
Molecular cloning and sequence analysis o f the cDNA for a human serine protease reponsible for 
activation o f hepatocyte growth factor. Structural similarity o f the protease precursor to blood 
coagulation factor XII. J.Biol.Chem., 265: 10024-10028, 1993.
106. Bottaro, D.P., Rubin, J.S., Faletto, D.L., Chan, A.M., Kmiecik, T.E., Vande, W.G., and Aaronson,
S.A. Identification o f the hepatocyte growth factor receptor as the c-met proto-oncogene product. 
Science, 251: 802-804, 1991.
107. Tamagnone, L. and Comoglio, P.M. Control o f invasive growth by hepatocyte growth factor 
(HGF) and related scatter factors. Cytokine.Growth Factor.Rev., 5: 129-142, 1997.
108. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., 
Aaronson, S., and Vande, W.G. Tumorigenicity of the met proto-oncogene and the gene for 
hepatocyte growth factor. Mol.Cell Biol., 72: 5152-5158, 1992.
109. Jeffers, M., Rong, S., and Vande, W.G. Enhanced tumorigenicity and invasion-metastasis by 
hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction 
of the urokinase proteolysis network. Mol.Cell Biol., 76: 1115-1125, 1996.
110. Yamashita, J., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., Saishoji, T., and Shin, S. 
Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and 
survival in human breast cancer. Cancer Res., 54: 1630-1633, 1994.
111. Ebralidze, A., Tulchinsky, E., Grigorian, M., Afanasyeva, A., Senin, V., Revazova, E., and 
Lukanidin, E. Isolation and characterization of a gene specifically expressed in different 
metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+- 
binding protein family. Genes Dev., i: 1086-1093, 1989.
112. Kriazhevskaia, M.V., Vorovch, M.F., Georgiev, G.P., and Lukanidin, E.M. [Mtsl protein in the 
cytoplasm o f metastasizing tumors]. Belok Mtsl v tsitoplazme metastazimiushchikh opukholei. 
Dokl.Akad.Nauk., 342: 259-261, 1995.
113. Takenaga, K., Nakamura, Y., Sakiyama, S., Hasegawa, Y., Sato, K., and Endo, H. Binding of 
pEL98 protein, an S 100-related calcium-binding protein, to nonmuscle tropomyosin. J.Cell Biol., 
124: 757-768, 1994.
74
114. Gibbs, F.E., Wilkinson, M.C., Rudland, P.S., and Barraclough, R. Interactions in vitro o f p9Ka, 
the rat S-100-related, metastasis-inducing, calcium-binding protein. J.Biol.Chem., 269: 18992- 
18999, 1994.
115. Davies, B.R., Barraclough, R., Davies, M.P., and Rudland, P.S. Production of the metastatic 
phenotype by DNA transfection in a rat mammary model. Cell Biol.Int., 77: 871-879, 1993.
116. Davies, B.R., Davies, M.P., Gibbs, F.E., Barraclough, R., and Rudland, P.S. Induction of the 
metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene 
for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene, 5: 999- 
1008, 1993.
117. Grigorian, M., Ambartsumian, N., Lykkesfeldt, A.E., Bastholm, L., Elling, F., Georgiev, G., and 
Lukanidin, E. Effect of mtsl (SI 00 A4) expression on the progression o f human breast cancer 
cells. Int.J.Cancer, 67: 831-841, 1996.
118. Grigorian, M.S., Tulchinsky, E.M., Zain, S., Ebralidze, A.K., Kramerov, D.A., Kriajevska, M.V., 
Georgiev, G.P., and Lukanidin, E.M. The mtsl gene and control of tumor metastasis. Gene, 735: 
229-238, 1993.
119. Takenaga, K., Nakamura, Y., and Sakiyama, S. Expression of antisense RNA to S100A4 gene 
encoding an SI 00-related calcium-binding protein suppresses metastatic potential o f high- 
metastatic Lewis lung carcinoma cells. Oncogene, 14: 331-337, 1997.
120. Ambartsumian, N.S., Grigorian, M.S., Larsen, I.E., Karlstrom, O., Sidenius, N., Rygaard, J., 
Georgiev, G., and Lukanidin, E. Metastasis o f mammary carcinomas in GRS/A hybrid mice 
transgenic for the mtsl gene. Oncogene, 73: 1621-1630, 1996.
121. Davies, M.P., Rudland, P.S., Robertson, L., Parry, E.W., Jolicoeur, P., and Barraclough, R. 
Expression of the calcium-binding protein S I00A4 (p9Ka) in MMTV-neu transgenic mice 
induces metastasis o f mammary tumours. Oncogene, 73: 1631-1637, 1996.
122. Kerr, J.F., Wyllie, A.H., and Currie, A.R. Apoptosis: a basic biological phenomenon with wide- 
ranging implications in tissue kinetics. Br.J.Cancer, 26: 239-257, 1972.
123. Deiss, L.P., Feinstein, E., Berissi, H., Cohen, O., and Kimchi, A. Identification o f a novel 
serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon- 
induced cell death. Genes Dev., 9: 15-30, 1995.
124. Cohen, O., Feinstein, E., and Kimchi, A. DAP-kinase is a Ca2+/calmodulin-dependent, 
cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its 
catalytic activity. EMBO J., 76: 998-1008, 1997.
125. Kissil, J.L., Feinstein, E., Cohen, O., Jones, P.A., Tsai, Y.C., Knowles, M.A., Eydmann, M.E., 
and Kimchi, A. DAP-kinase loss o f expression in various carcinoma and B-cell lymphoma cell 
lines: possible implications for role as tumor suppressor gene. Oncogene, 75: 403-407, 1997.
126. Inbal, B., Cohen, O., Polak, C.S., Kopolovic, J., Vadai, E., Eisenbach, L., and Kimchi, A. DAP 
kinase links the control o f apoptosis to metastasis. Nature, 390: 180-184, 1997.
127. Shtivelman, E. A link between metastasis and resistance to apoptosis o f variant small cell lung 
carcinoma. Oncogene, 14: 2167-2173, 1997.
128. Pena, J.C., Rudin, C M., and Thompson, C.B. A Bcl-xL transgene promotes malignant conversion 
of chemically initiated skin papillomas. Cancer Res., 58: 2111-2116, 1998.
129. Kaufmann, A.M., Lichtner, R.B., Schirrmacher, V., and Khazaie, K. Induction of apoptosis by 
EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour 
metastasis. Oncogene, 73: 2349-2358, 1996.
75
130. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K.J., and Takahashi, H. Expression of Fas ligand in 
liver métastasés o f human colonic adenocarcinomas. Proc.Natl.Acad.Sci.U.S.A., 94: 6420-6425, 
1997.
131. Gleave, M., Hsieh, J.T., Gao, C.A., von, E.A., and Chung, L.W. Acceleration o f human prostate 
cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 
3753-3761, 1991.
132. Fitzer, A.C., Do, M.S., Feigelson, S., Vadai, E., Feldman, M., and Eisenbach, L. Modification of 
PDGFalpha receptor expression or function alters the metastatic phenotype of 3LL cells. 
Oncogene, 15: 1545-1554, 1997.
133. Nicolson, G.L. and Dulski, K.M. Organ specificity of metastatic tumor colonization is related to 
organ-selective growth properties of malignant cells. Int.J.Cancer, 38: 289-294, 1986.
134. Libermann, T.A., Nusbaum, H R., Razon, N., Kris, R., Lax, 1., Soreq, H., Whittle, N., Waterfield, 
M.D., Ullrich, A., and Schlessinger, J. Amplification, enhanced expression and possible 
rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature,
313: 144-147, 1985.
135. Nicolson, G.L. Cancer progression and growth: relationship o f paracrine and autocrine growth 
mechanisms to organ preference of metastasis. Exp.Cell Res., 204: 171-180, 1993.
136. Senin, V.M., Buntsevich, A.M., Afanasyeva, A.V., and Kiseleva, A.V. A new line of murine 
carcinoma. Experimental Oncology, 5: 35-39, 1990.
137. Senin, V.M., Ivanov, A.M., Afanasyeva, A.V., and Buntsevich, A.M. A new line of murine 
metastatic tmasplanted tumors of mice and their use for sudying laser effect on dissemination. 
Vestnik USSR Academy o f Medical Sciences, 5: 85-91, 1993.
138. Barnett, S.C. and Eccles, S.A. Studies of mammary carcinoma metastasis in a mouse model 
system. I: Derivation and characterization o f cells with different metastatic properties during 
tumour progression in vivo. Clin.Exp.Metastasis, 2: 15-36, 1984.
139. Sonnenberg, A., Daams, H., Calafat, J., and Hilgers, J. In vitro differentiation and progression of 
mouse mammary tumor cells. Cancer Res., 46: 5913-5922, 1986.
140. Aslakson, C.J. and Miller, F.R. Selective events in the metastatic process defined by analysis of 
the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res., 52: 
1399-1405, 1992.
141. Bahler, D.W., Lord, E.M., Kennel, S.J., and Horan, P.K. Heterogeneity and clonal variation 
related to cell surface expression of a mouse lung tumor-associated antigen quantified using flow 
cytometry. Cancer Res., 44: 3317-3323, 1984.
142. Olsson, L. and Forchhammer, J. Induction o f the metastatic phenotype in a mouse tumor model 
by 5-azacytidine, and characterization of an antigen associated with metastatic activity. 
Proc.Natl.Acad.Sci.U.S.A., 81: 3389-3393, 1984.
143. Reznikoff, C.A., Brankow, D.W., and Heidelberger, C. Establishment and characterization o f a 
cloned line o f C3H mouse embryo cells sensitive to postconfluence inhibition o f division. Cancer 
Res., 33: 3231-3238, 1973.
144. Liang, P. and Pardee, A.B. Differential display of eukaryotic messenger RNA by means of the 
polymerase chain reaction. Science, 257: 967-971, 1992.
145. Chomczynski, P. and Sacchi, N. Single-step method o f RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform extraction. Anal.Biochem., 162: 156-159, 1987.
76
146. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular cloning. Sambrook, J., Fritsch, E. F., and 
Maniatis, T. 1989. Cold Spring Harbor, NY, Cold Spring Harbor Press.
147. Klingelhofer, J., Ambartsumian, N.S., and Lukanidin, E.M. Expression of the metastasis- 
associated mtsl gene during mouse development. Dev.Dyn., 2JO: 87-95, 1997.
148. Kramerov, D.A., Bukrinsky, M.I., and Ryskov, A.P. DNA sequences homologous to long double­
stranded RNA. Transcription of intracistemal A-particle genes and major long repeat of the 
mouse genome. Biochim.Biophys.Acta, 826: 20-29, 1985.
149. Callahan, R. MMTV-induced mutations in mouse mammary tumors: their potential relevance to 
human breast cancer. Breast Cancer Res.Treat., 39: 33-44, 1996.
150. Zhidkova, N.I., Justice, S.K., and Mayne, R. Alternative mRNA processing occurs in the variable 
region o f the pro-alpha 1(XI) and pro-alpha 2(XI) collagen chains. J.Biol.Chem., 270: 9486- 
9493, 1995.
151. Christensen, C.R., Klingelhofer, J., Tarabykina, S., Hulgaard, E.F., Kramerov, D., and Lukanidin,
E. Transcription o f a novel mouse semaphorin gene, M-semaH, correlates with the metastatic 
ability of mouse tumor cell lines. Cancer Res., 58: 1238-1244, 1998.
152. Cohn, M.A., Kramerov, D., Hulgaard, E.F., and Lukanidin, E.M. The differentiation antigen Ly- 
6E.1 is expressed in mouse metastatic tumor cell lines. FEBS Lett., 403: 181-185, 1997.
153. Gautheret, D., Poirot, O., Lopez, F., Audic, S., and Claverie, J.M. Alternate polyadenylation in 
human mRNAs: A large-scale analysis by EST clustering [In Process Citation]. Genome Res., 8: 
524-530, 1998.
154. Kozak, M. Structural features in eukaryotic mRNAs that modulate the initiation o f translation. 
J.Biol.Chem., 266: 19867-19870, 1991.
155. Yang, X., Nakao, Y., Pater, M.M., and Pater, A. Identification of two novel cellular genes 
associated with multistage carcinogenesis o f human endocervical cells by mRNA differential 
display. Carcinogenesis, 77: 563-567, 1996.
156. Sun, Y., Hegamyer, G., and Colburn, N.H. Molecular cloning of five messenger RNAs differen­
tially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to 
human tissue inhibitor o f metalloproteinases-3. Cancer Res., 54: 1139-1144, 1994.
157. Bauer, D., Muller, H., Reich, J., Riedel, H., Ahrenkiel, V., Warthoe, P., and Strauss, M. 
Identification o f differentially expressed mRNA species by an improved display technique 
(DDRT-PCR). Nucleic.Acids.Res., 27: 4272-4280, 1993.
158. Zhang, L., Zhou, W., Velculescu, V.E., Kem, S.E., Hmban, R.H., Hamilton, S.R., Vogelstein, B., 
and Kinzler, K.W. Gene expression profiles in normal and cancer cells. Science, 276: 1268-1272, 
1997.
159. Seidah, N.G., Benjannet, S., Pareek, S., Savaria, D., Hamelin, J., Goulet, B., Laliberte, J., Lazure, 
C., Chretien, M., and Murphy, R.A. Cellular processing of the nerve growth factor precursor by 
the mammalian pro-protein convertases. Biochem.J., 374: 951-960, 1996.
160. Fulle, S., Mariggio, M.A., Belia, S., Nicoletti, L, and Fano, G. Nerve growth factor inhibits 
apoptosis induced by S-100 binding in neuronal PC12 cells. Neuroscience, 76: 159-166, 1997.
161. Katoh, S., Mitsui, Y., Kitani, K., and Suzuki, T. Nerve growth factor rescues PC 12 cells from 
apoptosis by increasing amount of bcl-2. Biochem.Biophys.Res.Commun., 229: 653-657, 1996.
77
162. Sato, H., Kinoshita, T., Takino, T., Nakayama, K., and Seiki, M. Activation o f a recombinant 
membrane type 1-matrix metalloproteinase (MTl-MMP) by furin and its interaction with tissue 
inhibitor o f metalloproteinases (TIMP)-2. FEBS Lett., 393: 101-104, 1996.
163. Mbikay, M., Sirois, F., Yao, J., Seidah, N.G., and Chretien, M. Comparative analysis o f  
expression of the proprotein convertases furin, PACE4, PCI and PC2 in human lung tumours. 
Br.J.Cancer, 75: 1509-1514, 1997.
164. Yoshioka, H., Inoguchi, K., Khaleduzzaman, M., Ninomiya, Y., Andrikopoulos, K., and Ramirez,
F. Coding sequence and alternative splicing of the mouse alpha 1(XI) collagen gene (Coll la 1). 
Genomics, 28: 337-340, 1995.
165. Yoshioka, H. and Ramirez, F. Pro-alpha 1(XI) collagen. Structure of the amino-terminal 
propeptide and expression of the gene in tumor cell lines. J.Biol.Chem., 265: 6423-6426, 1990.
166. Varner, J.A. and Cheresh, D.A. Integrins and cancer. Curr.Opin.Cell Biol., 8: 724-730, 1996.
167. Meredith-JE, J., Fazeli, B., and Schwartz, M.A. The extracellular matrix as a cell survival factor 
Mol.Biol.Cell, 4: 953-961, 1993.
168. Tuckwell, D., Calderwood, D.A., Green, L.J., and Humphries, M.J. Integrin alpha 2 I-domain is a 
binding site for collagens. J.Cell Sci., 108: 1629-1637, 1995.
169. Stewart, C. and Burke, B. Teratocarcinoma stem cells and early mouse embryos contain only a 
single major lamin polypeptide closely resembling lamin B. Cell, 51: 383-392, 1987.
170. Machiels, B.M., Ramaekers, F.C., Kuijpers, H.J., Groenewoud, J.S., Oosterhuis, J.W., and 
Looijenga, L.H. Nuclear lamin expression in normal testis and testicular germ cell tumours of 
adolescents and adults. J.Pathol., 182: 197-204, 1997.
171. Gabrijelcic, D., Svetic, B., Spaic, D., Skrk, J., Budihna, M., Dolenc, L, Popovic, T., Cotic, V., and 
Turk, V. Cathepsins B, H and L in human breast carcinoma. Eur.J.Clin.Chem.Clin.Biochem 30- 
69-74, 1992.
172. Lah, T.T., Kokalj, K.M., Drobnic, K.M., Babnik, J., Golouh, R., Vrhovec, L, and Turk, V. 
Cystatins and cathepsins in breast carcinoma. Biol.Chem.Hoppe Seyler, 373: 595-604, 1992.
173. Guinée, N., Dalet, F.V., and Pagano, M. "In vitro" study of basement membrane degradation by 
the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, 
flbronectin, and release of gelatinase activities from basement membrane flbronectin. 
Biol.Chem.Hoppe Seyler, 574; 1135-1146, 1993.
174. Guenette, R.S., Mooibroek, M., Wong, K., Wong, P., and Tenniswood, M. Cathepsin B, a 
cysteine protease implicated in metastatic progression, is also expressed during regression o f the 
rat prostate and mammary glands. Eur.J.Biochem., 226: 311-321, 1994.
175. Sloane, B.F., Rozhin, J., Moin, K., Ziegler, G., Fong, D., and Muschel, R.J. Cysteine 
endopeptidases and their inhibitors in malignant progression of rat embryo fibroblasts. 
Biol.Chem.Hoppe Seyler, 373: 589-594, 1992.
176. Katz, B.Z., Eshel, R., Sagi, A.O., and Witz, I.P. An association between high Ly-6A/E expression 
on tumor cells and a highly malignant phenotype. Int.J.Cancer, 59: 684-691, 1994.
177. Davies, A., Simmons, D.L., Hale, G., Harrison, R.A., Tighe, H., Lachmann, P.J., and Waldmann, 
H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action o f the 
complement membrane attack complex on homologous cells. J.Exp.Med., 170: 637-654, 1989.
178. Birchmeier, W., Hulsken, J., and Behrens, J. E-cadherin as an invasion suppressor. 
Ciba.Found.Symp., 189: 124-136, 1995.
78
179. Pyke, C., Salo, S., Ralfkiaer, E., Romer, J., Dano, K., and Tryggvason, K. Lamin in-5 is a marker 
o f  invading cancer cells in some human carcinomas and is coexpressed with the receptor for 
urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas Cancer Res 
55: 4132-4139, 1995.
79
